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ABSTRACT 
Neuroplasticity is defined as an ability of the nervous system to change when it 
responds to modified environmental or internal conditions. Functional 
neuroplasticity enables a change in behaviour and ultimately provides a major 
mechanism for enhanced survival in a given environment. There are two main 
types of plasticity, positive and negative plasticity. Positive plasticity describes 
abilities and brain processes that benefit an animal. Negative plasticity is related 
to processes that tend to be harmful. In this study, positive neuroplasticity was 
investigated in relation to aggressive behaviour and processing of novel signals; 
processes that are both required for successful survival in a changing habitat. 
Negative plasticity was studied in several stages of addiction, a psychiatric 
disease in which normal plasticity is interfered by drugs of abuse eventually 
leading to compulsive drug use. The neurotransmitter glutamate has a well-
established role in chemical signalling between neurons, and an emerging role 
as a major component regulating neuroplasticity. Glutamate receptors of !-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type are 
tetramers composed of subunits GluA1-4 and they mediate a majority of the 
fast synaptic neurotransmission, that is also implicated in neuroplastic 
processes. Here, the AMPA receptor subunit GluA1-deficient mouse line 
(GluA1-KO mouse line) was studied using behavioural and neurochemical 
approaches. GluA1-KO mouse line provides an alternative approach to study 
the importance of AMPA receptors in neuroplasticity, as there are no subunit-
selective pharmacological ligands available. GluA1-KO mice displayed less 
propensity to change their agonistic behaviour when exposed to an altered 
social environment in comparison with wild-type (WT) control mice, increased 
responsiveness towards spatial novelty followed by deficient habituation, 
decreased capability to develop tolerance to benzodiazepine flurazepam, and 
defective morphine-induced state-dependency. Taken together, these results 
propose a bidirectional role for GluA1 subunit in positive and negative 
neuroplastic processes. In summary, these results strengthen the role of GluA1 
subunit in neuroplasticity, and may assist future drug development in disorders 
in which neuroplasticity plays a role. 
  
 7 
LIST OF ORIGINAL PUBLICATIONS 
This thesis is based on the following publications, referred in the text by their 
roman numerals: 
 
 
 
I Vekovischeva OY, Aitta-aho T, Echenko O, Kankaanpää A, Seppälä 
 T, Honkanen A, Sprengel R, Korpi ER. Reduced aggression in AMPA-
 type glutamate receptor GluR-A subunit-deficient mice. Genes Brain 
 Behav. 2004;3:253-65. 
 
II Procaccini C*, Aitta-aho T*, Jaako-Movits K, Zharkovsky A, 
 Panhelainen A, Sprengel R, Linden AM, Korpi ER. Excessive novelty-
 induced c-Fos expression and altered neurogenesis in the hippocampus 
 of GluA1 knockout mice. Eur J Neurosci. 2011;33:161-74. 
 
III Aitta-aho T, Vekovischeva OY, Neuvonen PJ, Korpi ER. Reduced 
 benzodiazepine tolerance, but increased flumazenil-precipitated 
 withdrawal in AMPA-receptor GluR-A subunit-deficient mice. 
 Pharmacol Biochem Behav. 2009;92:283-90. 
 
IV Aitta-aho T, Möykkynen TP, Panhelainen AE, Vekovischeva OY, 
 Bäckström P, Korpi ER. Importance of AMPA receptor GluA1 
 subunit for morphine state-dependency. Submitted. 
 
 
*Equal contribution 
 
 
The original publications are reprinted with the permission of the copyright 
holders. 
 
 
  
 8 
ABBREVIATIONS 
 
5-HT  5-hydroxytryptophan, serotonin 
AMPA  !-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ANOVA analysis of variance 
BrdU  bromodeoxyuridine 
CA  cornu ammonis of the hippocampus 
CaMK2A calcium!calmodulin-dependent protein kinase II alpha 
CNS  central nervous system 
CS  conditioned stimulus 
DA  dopamine 
DG  dentate gyrus 
DL-AP5 racemic (2R)-amino-5-phosphonovaleric acid 
DNA  deoxyribonucleic acid 
EAAT  excitatory amino acid transporter 
EPSP  excitatory postsynaptic potential 
GABA  "-aminobutyric acid 
GABAA "-aminobutyric acid type A receptor 
GAD  glutamic acid decarboxylase 
GPCR  G-protein-coupled receptor 
HPLC  high-performance liquid chromatography 
IEG  immediate-early genes 
KO  knockout 
LTD  long-term depression 
LTP  long-term potentiation 
mGluR  metabotropic glutamate receptor 
mRNA  messenger RNA 
NAc  nucleus accumbens 
NSF  N-ethylmaleimide-sensitive factor 
NMDA N-methyl-D-aspartate 
PCR  polymerase chain reaction 
PICK1  protein interacting with C kinase 1 
RNA  ribonucleic acid 
SHIRPA SmithKline Beecham-Harwell-Imperial College-Royal  
  London Hospital-phenotype assessment 
SYM 2081 (2S, 4R)-4-methylglutamate 
US  unconditional stimulus 
VGLUT vesicular glutamate transporter 
VTA  ventral tegmental area 
WT  wild-type 
  
 9 
1 INTRODUCTION 
Neuroplasticity is defined as an ability of the nervous system to change when it 
responds to modified environmental conditions, brain trauma or degenerative 
change. Plasticity also can occur within the brain network itself, which can 
furthermore be initiated by external stimuli. Behaviour related to social 
interaction, processing of novel signals and to drugs of abuse is subject to 
change in response to experience-related stimuli. These changes are based on 
modifications between the basic units of communication in the brain, the 
neurons. Glial cells have also been suggested as becoming increasingly 
important in the modulation of synaptical communication. Two main signal 
modalities exist that mediate the information from neuron to neuron. These 
include electrical signals that propagate within the neurons, and chemical ones 
that send messages between the neurons across a synapse. 
An outcome-based division of plasticity describes two directions of 
plasticity. Positive plasticity describes changes that benefit an animal while 
negative plasticity describes changes that eventually tend to be harmful. 
Aggression and processing of novel signals are related to the positive plasticity. 
For example, a change in a social environment might warrant activation of 
aggressive behaviour in order to survive, and proper responding towards 
novelty promotes orderly perception that enables learning. In contrast, the 
latter type of plasticity can be caused by drugs of abuse. Drug use modifies 
brain function by causing an array of processes underlying the behavioural 
changes known as addiction. 
Glutamate is an amino acid that is primarily responsible for the main 
excitatory signalling. Chemical neurotransmission is initiated by the arrival of 
electrical action potential to the presynaptic neuron, where glutamate is 
released in highly controlled manner. When glutamate reaches the postsynaptic 
neuron, it activates a diverse class of glutamate receptor proteins. Of these, !-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type receptors 
mediate the fast excitatory neurotransmission leading to excitatory postsynaptic 
potential in response to cation influx to neurons. However, AMPA receptors 
are instrumental in neuroplasticity underlying changes in behaviour. The 
foundation of activity-dependent change between the neurons involves either 
insertion or removal of AMPA receptors at synaptic cell membrane leading to 
long-term potentiation (LTP) or long-term depression (LTD), respectively. 
These models of activity-dependent change in neuronal communication are 
thought as cellular correlates of neuroplasticity in its various forms. 
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2 REVIEW OF THE LITERATURE 
2.1 BEHAVIOURAL PLASTICITY 
By definition, plasticity is an ability to change over time. Behavioural plasticity, 
a change in behaviour, is of primary importance as it allows adaptation to the 
changes in environment, and thus increases survival. Changes in environment 
can originate from a decrease in food sources, modified social constructs and 
an increase in the number of other individuals in the same habitat. In all of 
these cases, the change in behaviour promoting survival is of a positive type; 
and can include learning new rules, memory of events and appropriate 
responses to the novel environment. However, plasticity can also have negative 
consequences. Environmental changes can lead to sustained stress, which can 
in-turn increase the risk of developing anxiety and depressive conditions. 
Activities such as games, drug use and shopping can interfere with the control 
of the underlying mechanisms of plasticity which can lead to behaviours 
related to addiction. 
 
2.2 CELLULAR AND MOLECULAR FOUNDATION 
FOR BEHAVIOURAL PLASTICITY 
 
Experience-related stimuli continuously modify the brain neuronal networks, a 
process that eventually results in changes in behaviour. These modifications 
underlying behavioural plasticity take place at various levels, including brain 
regional, morphological and molecular one levels. Changes in the volume of 
distinct brain regions have been observed as being linked to neuroplastic 
events such as learning or drug abuse (Anderson et al. 2002; Bartzokis et al. 
2000). At the morphological level, neuronal activity can promote dendritic 
outgrowth, synapse elimination, and remodelling of dendritic spines (for 
review, see McKinney 2010). However, these changes are under the control of 
molecular determinants of plasticity including modifications in e.g. receptors, 
neurotrophic factors, second messengers, immediate-early genes (IEGs) and 
gene expression. 
At the cellular level, the most widely studied forms of neuroplasticity are 
LTP and LTD (Bliss and Lømo 1973). These represent a long-lasting change in 
the synaptic strength between two neurons that is due to repeated and 
synchronous stimulation of them. These phenomena occur in various kinds of 
synapses. It has even been suggested that all the neuronal connections possess 
an ability to show synaptic LTP and/or LTD (reviewed in Malenka and Bear 
2004). Typically, LTP is generated by a brief electrical stimulation of 
presynaptic neuron that activates postsynaptic glutamate N-methyl-D-aspartate 
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(NMDA) receptors. This results in the elevation of intracellular Ca2+ for a time 
period as short as 2-3 seconds (Malenka et al. 1992). Thereafter, rapid insertion 
of AMPA receptors to the plasma membrane by trafficking mechanisms (see 
chapter 2.7.4) causes the expression of LTP (Hayashi et al. 2000), while 
removal of plasma membrane AMPA receptors leads to the expression of 
LTD (Beattie et al. 2000). After the acute phase of increase in synaptic efficacy, 
the sustained potentiation will require protein synthesis (Frey et al. 1988). Apart 
from plasticity occurring at the synaptic level, neuron-scale intrinsic plasticity 
has also been shown to exist in the central nervous system (CNS) (for review, 
see Zhang and Linden 2003). 
At the molecular level, change in the number and properties of receptors is 
one of a diverse class of mechanisms behind neuroplasticity. These are 
reviewed in chapter 2.7, with a special reference to AMPA receptors. There are 
also other well-established molecular substrates involved in neuroplasticity. 
IEGs are an example of this and are a heterogeneous family comprising 
hundreds of members including,  transcription factors, enzymes, cytokines and 
neurotrophic factors (Herschman 1991; Fowler et al. 2011). Alterations in 
IEGs can correlate with the plasticity-inducing experience. Some of these 
genes include activity-regulated cytoskeleton-associated protein (arc), c-fos, fosB 
and deltaFosB (Bramham et al. 2008; Lanahan and Worley 1998). Of the 
neurotrophic factors, brain-derived neurotrophic factor (BDNF) is probably 
best studied in relation to plasticity (for review, see McAllister et al. 1999). The 
role of BDNF in plasticity relates to several lines of evidence. This being that 
BDNF is present in brain areas known for their role in plasticity such as 
hippocampus and cerebral cortex, that brain activity regulates BDNF 
messenger RNA (mRNA) expression in these brain regions, and that BDNF 
has been shown as having a role in synaptic plasticity in LTP (for review, see 
McAllister et al. 1999; Malenka and Bear 2004). Finally, also cyclic adenosine 
monophosphate and its response element binding protein regulate gene 
expression that affects biosynthesis of a variety of proteins leading to enduring 
changes in the CNS (Chrivia et al. 1993). 
 
2.3 APPROACHES TO STUDY POSITIVE AND 
NEGATIVE PLASTICITY 
Appropriate aggressive behaviour in mice is instrumental in survival and 
reproduction as it enables both an increase, in the rank of individual as a 
member of a habitat (e.g. by assuring better sources for nutrition) and the 
possibility of finding a suitable mating partner (Bronson 1979). Novel signals 
provides the opportunity for finding better resources thus promoting survival 
(Panksepp 1998). Proper processing of information elicited by novel signals 
provides a platform for perception and subsequent encoding of these signals 
(Vinogradova 2001). Plasticity due to drug abuse leads to behaviours that are 
the core characteristics of addiction, compulsive and continuing drug use 
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despite the negative consequences. These harmful outcomes can be, but not 
limited to, an increased risk of mental and physical disorders, job loss, loss of 
custodial rights and committing of crimes leading to legal actions (World 
Health Organization 1999). 
2.3.1 AGGRESSIVE BEHAVIOUR 
 
Aggressive behaviour can be hostile, destructive and injurious actions that are 
directed towards the self, others or objects (Swann 2003). In humans, 
aggression can occur comorbidly with several psychiatric illnesses or disorders. 
Aggressive behaviour can be caused by defects in perception and cognition in 
psychosis, by traumatic events in patients with post-traumatic stress disorder, 
by psychopathy in antisocial personality disorder and by increased emotional 
sensitivity in borderline personality disorder (Siever 2008). Aggressive 
behaviour is part of agonistic behaviours that are social behaviours related to 
fighting (Scott 1966). Agonistic behaviour is a more extensive term than 
aggression, since it also covers behaviours (such as threatening, displays, 
postures and defensive behaviours) that show the intention of, not the actual 
act of aggression (Scott 1966). 
Brain circuitry mediating aggression consists of several components. 
Evaluation and decision-making processes which regulate the action of 
aggression stem from the prefrontal cortex (Davidson and Irwin 1999). 
Lesions in these areas may lead to increase in aggressive behaviour (Damasio et 
al. 1994). Cortical areas signal the limbic system, most notably to amygdala, 
which is critical in associative learning related to aggression (Hollander and 
Gallagher 1999). Thus, the amygdala enables the linkage of unconditional 
aggressive events with the cues that remind of these events. This process can 
be seen as classical conditioning (Hollander and Gallagher 1999). Lesions that 
damage amygdala cause dysfunctions in recognition of facial expressions, also 
those related to aggression (Adolphs et al. 1994). In contrast to this, patients 
with borderline personality disorder (see above) show overactivation of the 
amygdala in response to positive, neutral and negative facial expressions 
(Donegan et al. 2003). Finally, the action of aggression is suggested to originate 
from the ventromedial hypothalamus (Lin et al. 2011). 
Several neurotransmitter systems and hormones have been linked to 
aggression. Serotonin, by acting on 5-HT2 receptors, activates prefrontal 
cortical regions and thereby increases control over aggressive emotions (Swann 
2003). Increases in serotonin transmission by selective serotonin reuptake 
inhibitors decreases aggressive behaviour (Coccaro and Kavoussi 1997). This 
may be mediated by an increased activation of prefrontal areas which in turn 
inhibit the amygdala (Davidson et al. 2000). Inhibitory and excitatory 
neurotransmitters "-aminobutyric acid (GABA) and glutamate, have been 
implicated in the modulation of aggressive behaviours. GABAA receptor 
positive modulators such as neurosteroid allopregnanolone (Fish et al. 2002), 
benzodiazepines (Takahashi et al. 2010) and ethanol (Miczek 2004) increase 
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aggression in low doses while high doses decrease aggression possibly via 
sedative actions. Increased glutamatergic tone leads to augmentation of 
aggressiveness in many species (Bullock and Rogers 1986; Munoz-Blanco et al. 
1986). The steroid hormone testosterone, and similar chemical entities, can 
also enhance aggression (Archer 1991). 
2.3.2 PROCESSING OF NOVEL SIGNALS 
 
Novelty, irrespective of the stimulus modality, evokes a response that has 
an elementary role in biology. Response to novelty, or orienting response, was 
first described as “!"# $"# "%&#'” or “what is this” reaction (Pavlov 1927). Its 
purpose is to direct an animal’s attention to perceive a change in the 
environment. Response to novelty can be detected in a wide variety of bodily 
functions such as dilatation in the pupil of the eye, sweat gland activity, 
respiration, heart rate and vascular activity. In the brain, novelty can be 
observed in various responses. Using electroencephalography or 
magnetoencephalography, changes in the activity of the alpha frequency (Barry 
2009) and in the event-related potentials related to novelty detection, such as 
P3 (reviewed in Friedman et al. 2001) and mismatch negativity (reviewed in 
Kujala and Näätänen 2010), can be detected. Of these, mismatch negativity is 
mediated by glutamate receptors of NMDA type (Javitt et al. 1996). 
Organisms react preferentially to novel information over familiar 
information. Response to novelty often undergoes subsequent decrease when 
the novel stimulus is repeated or constantly presented (Rankin et al. 2009), thus 
finally the stimulus elicits no response. This is known as habituation. The 
significance of habituation lies in making sure the system remains reactive to 
novel stimuli, that is, preserving a positive signal-to-noise ratio. Habituation 
has been considered as one of the most simple forms of learning, although this 
notion probably only includes the phenomenon of habituation. The 
neuroplastic mechanisms of habituation remain, however, largely unexplained 
(Rankin et al. 2009). 
The detection of novelty and habituation of the novelty response are 
mediated by various circuitries in the CNS, although the hippocampus has 
received most of the attention. In subjects with hippocampal damage, novelty-
related brain responses (see above) are not detected (Knight 1996), and 
hippocampal lesions render subjects incapable of habituating to novelty 
(Vinogradova 2001). Thus, the hippocampus has been suggested to act as a 
detector of novel signals, comparing these signals with the older ones 
(Vinogradova 2001). The hippocampus is strongly innervated by glutamatergic 
neurons, and thus not surprisingly, response to novelty and habituation are 
mediated by glutamatergic signalling (Leussis and Bolivar 2006). In the 
midbrain, the ventral tegmental area (VTA) contains dopamine (DA) neurons 
that provide a substantial response to novelty (Kovacs 1998). Finally, the 
nucleus accumbens (NAc), is a brain region postulated to play a role in 
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novelty-related behaviours and is a place of convergence for glutamate and 
dopamine (DA) neurons (Beckstead 1979). 
Novelty-induced response evokes patterns of activation in the CNS that can 
also be detected using IEG-based strategies (Kovacs 1998). Among these 
genes, c-fos is probably the most widely used marker of neuronal activity. The 
most common approach used to study this gene are to detect either its mRNA 
c-fos or its protein product c-Fos.  
Novelty induces a wide array of effects in brain regional c-Fos expression. 
Increased expression of c-Fos protein has been localised to the hippocampus, 
amygdala, cortex, thalamic regions and midbrain regions (Kovacs 1998; 
Ryabinin et al. 1999). In addition to the use as a marker of neuronal activation, 
c-Fos has also been implicated in the processes of plasticity (Fleischmann et al. 
2003). Thus, experiences that modify the expression of c-fos might have 
plasticity-related effects through this gene. 
2.3.3 DRUG ADDICTION 
 
Addiction is a chronic and relapsing disorder that causes direct and indirect 
harms to an individual and for society, in social and medical problems as well 
as loss of productivity. It has been estimated that in the year 2010, costs related 
to addiction were 66 billion euros (Olesen et al. 2012). In Finland, 13% of the 
population from the age of 15-69 years reported to have used an illicit drug at 
some point of their lives, and 90% of population reported to use of alcohol 
(National Institute for Health and Welfare, 2010). However, disparity exists 
between the prevalence of drug use and drug abuse. In Finland, the prevalence 
of illicit drug abuse is estimated at 1%, and for alcohol 6% (Halme et al. 2008; 
National Institute for Health and Welfare, 2010). For benzodiazepines, 6% of 
the Finnish population has been estimated to use these drugs annually, and 
while there are no statistics of benzodiazepine dependence in Finland, 
dependence has been estimated to be around 1% (Vorma 2003). 
The disease of addiction has many causes that exist in parallel. These can be 
related to social issues, self-medication of a condition (e.g. pain or anxiety), or 
unintentional exposure to a drug of abuse (Marlatt et al. 1988; McLellan et al. 
2000). When the process that eventually leads to addiction is presented in 
chronologically, the first event is the rewarding effect that drugs of abuse 
induce. The sense of well-being caused by drugs of abuse tend to have 
reinforcing properties, that is, the behaviour of drug taking is repeated (White 
1989). Already, the first dose is able to modulate the brain in a morphological 
and functional way, thus possibly laying the foundation to the addictive 
behaviour (Ungless et al. 2001). When the drug use continues, an additional 
modification, the development of tolerance, takes place that leads to reduction 
in the effect of a certain drug dose. This type of plasticity also promotes 
continued drug use and increasing of the drug dosage. At the time of 
withdrawal the nervous system is in an adapted state of dependence, and 
usually the withdrawal symptoms that emerge are opposite to the initial drug 
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effects. Euphoria turns into dysphoria, anxiolysis turns into anxiety, liveliness 
turns into exhaustion, and confidence turns into uncertainty (World Health 
Organization 2007). Confrontation with such strong negative feelings may 
further encourage drug taking. However, the definition of addiction include yet 
another critical features, which are the relapsing nature of the disease despite 
long-lasting breaks in the drug use and compulsion in drug seeking and taking 
(World Health Organization 2007). These behaviours are not easily attributable 
exclusively to the rewarding and withdrawal-causing properties of abused 
drugs. As the drug use continues, the rewarding properties of the drug become 
harder to gain, and some classes of abused drugs like psychostimulants 
amphetamine and cocaine lead to non-existent, or at the most, mild 
withdrawal. Thus, as reward, tolerance and withdrawal are important features 
in addiction, a more complex neuroplasticity must underlie the addictive 
behaviour as a whole. 
2.3.3.1 Sensitisation and tolerance 
 
Sensitisation describes a plastic event in which a response caused by a stimulus 
is enhanced when the stimulus is repeated (Steketee and Kalivas 2011). In 
relation to drugs of abuse, behavioural sensitisation develops in consequence 
of repeated administration of the drug, leading to enhanced motor response in 
experimental animals. Although the induction and expression of sensitisation is 
normally caused by the same drug, different classes of drugs of abuse are able 
to sensitise each other’s response, that is, cross-sensitisation occurs among 
wide array of drugs of abuse. This suggests a common neuronal substrate 
underlying sensitisation (for review, see Steketee and Kalivas 2011). The 
foundations of sensitisation have implicated the mesocorticolimbic system, 
more specifically to VTA, NAc, prefrontal cortex and amygdala. Between these 
regions, neurotransmitters glutamate, DA and GABA have an established role 
for sensitisation signalling (Kalivas and Weber 1988; Wolf et al. 1995; 
Tecuapetla et al. 2010). Addiction theory of incentive-sensitisation describes a 
proposed process in which the sensitivity to want the drug is enhanced 
(Robinson and Berridge 1993). 
Tolerance describes a reduction in the response when the stimulus is 
repeated. Thus the phenomenon of tolerance is opposite to that of 
sensitisation, at least at the level of definition. Thus, tolerance is a plastic event, 
that might be related to the self-defensive process of the biological system to 
resist, or tolerate, a high exposure to an exogenous chemical. In the time-
course of addiction, tolerance has a pivotal role. Due to the reinforcing 
properties of drugs of abuse, dose escalation tends to occur which in turn 
causes tolerance to the pleasurable effects of the drug (Hyman and Malenka 
2001). Increases in drug taking may then enhance the propensity of the 
addiction-related plastic changes to develop. For certain drug classes like 
opioids, the neuroplastic processes have been extensively elucidated (reviewed 
in: Williams et al. 2001). In general, several different processes might co-exist 
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such as desensitisation of the receptor, downregulation of receptor protein, 
recycling of receptors, circuitry-level compensations and modifications in gene 
expression. 
 
 
 
 
 
 
 
 
 
Figure 1. Place conditioning and state-dependency. (A) In place conditioning, a 
vehicle injection is paired with a neutral stimulus (squares) thus representing a 
conditioning stimulus minus trial, and drug injection with unconditional stimulus 
properties with another neutral stimulus (circles) thus representing a conditioning 
stimulus plus trial. In the test trial, both neutral stimuli are represented to choose 
from. If the drug-paired, previously neutral stimulus, elicits approach behaviour, it 
has acquired conditioned stimulus properties shown as place preference. The 
previously neutral stimulus has thus become conditioned stimulus. If the drug-
paired stimulus elicits avoidance behaviour, it has acquired aversive stimulus 
properties shown as place avoidance. (B) Drug injection can produce an affective 
state which is present during the conditioning trial. State-dependency describes a 
situation when the test trial is performed in the same state as the conditioning. In 
contrast to that, testing can be performed in a vehicle state as shown in (A). 
Abbreviations: CS+, conditioning stimulus plus trial; CS-, conditioning stimulus 
minus trial; US, unconditional stimulus. 
  
A B
Conditioning
Testing
CS+CS-
vehicle drug = US
vehicle
Conditioning
Testing
CS+CS-
vehicle drug = US
drug
 17 
2.3.3.2 Pavlovian conditioning and state-dependency 
 
In the conditioning process, a neutral stimulus lacking any clear response is 
paired with a stimulus that is able to produce a response in its own right thus 
termed an unconditional stimulus (US). After the pairing procedure, the then 
neutral stimulus acquires conditional stimulus properties therefore becoming 
conditioned stimulus (CS). When the CS is presented, it provokes a 
conditioned response (Pavlov 1927). Pavlovian conditioning, also termed 
classical or respondent conditioning, involves involuntary unconditional 
responses. In contrast to this, operant conditioning describes learning process 
in which an animal can control the behavioural consequences during the 
conditioning, consequently having voluntary actions playing a role in the 
process (Skinner 1981). In general, conditioning is a fundamental learning 
process that takes place in various fields of life and in several different species 
(Pavlov 1927; Hawkins et al. 1983; Schiller et al. 2009). Place conditioning 
procedure is described in Figure 1 as a type of Pavlovian conditioning. 
Drug use and the rewarding feelings caused by it can be associated with 
environmental stimuli (also termed cues), through the process of Pavlovian 
conditioning (Shaham et al. 2003). The cue can be a certain place, people, 
music, smell or paraphernalia related to drug use such as needles and cigarette 
holder (Carter and Tiffany 1999). Thus, various common sensory modalities 
are covered, including visual, tactile, olfactory, gustatory and auditory. Usually 
the cue is not of a single modality, but a combination of many stimuli 
(Cunningham et al. 2006). Compound CS can have enhanced efficacy in acting 
as a CS compared to single element CS (Everitt and Robbins et al. 2005). After 
this process, the cues can also produce the same or similar effects as the drug. 
Drug-related cues can also precipitate relapse despite long periods of 
abstinence (Shaham et al. 2003), thus having a pivotal role in the critical feature 
of addiction. In addition to cue-induced relapse, also the drug itself can 
reinstate drug taking behaviour. In this case, a lower dose usually is able to 
produce the conditioned effect which may be attributable to the sensitisation 
of the processes (Robinson and Berridge 1993; Steketee and Kalivas 2011). 
State-dependency describes a behavioural phenomenon in which the 
information retrieval is most efficient when an individual is in the same state as 
they were during the information acquisition. Usually the state is defined as an 
intrinsic affect, which can be formulated in a number of ways. Mood (Bower 
1981), sleep (Patti et al. 2010) and drugs (Bruins Slot and Colpaert 1999) have 
been shown to create states which contribute to acquisition and retrieval of 
information. Drugs of abuse can therefore, form a state that can act as a cue in 
the learning process related to addiction. As a result, state-dependency may 
contribute to relapse behaviour when the drug-formed state is again achieved. 
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2.3.3.3 Neuroplastic properties of morphine and 
benzodiazepines 
 
Opium, a white fluid derived from opium poppy, Papaver somniferum, is the 
etymological origin for the opioid neurotransmitter system that comprises four 
G-protein coupled receptors (µ, #, $ and orphan) and several endogenously 
synthesised opioid peptides (for review, see Kieffer and Evans 2009). 
However, opium poppy-derived morphine is considered the prototypical 
ligand in the opioid system, with the effects of morphine well describing the 
wide functional distribution of the opioid system in the body. Sedative, 
euphoric, constipation-causing, immune system-acting, analgetic, antitussive 
and addictive properties of morphine indicate that the opioid system is having 
roles in both central and peripheral locations. Morphine binds to µ, #, and $ 
opioid receptors which are linked to inhibitory G-proteins, causing inhibition 
of adenylate cyclase which then leads to decrease in second messenger cyclic 
adenosine monophosphate. Brain regional localisation of opioid receptor 
covers almost the entire CNS. For example, the hippocampus, thalamus, 
cortex, striatum, midbrain and spinal cord have strong expression of these 
receptors (Le Merrer et al. 2009). 
Benzodiazepines are small-molecular weight synthetic chemicals that act as 
positive modulators in anion-permeable GABAA receptors (for review, see 
Möhler 2011). As GABA is the main inhibitory neurotransmitter in the brain, 
the enhanced inhibition enables the use of benzodiazepines as sedative, 
hypnotic, anxiolytic, muscle relaxant and an anticonvulsant. Benzodiazepine 
binding to GABAA receptors is determined by the subunit composition. The 
benzodiazepine binding site resides between the ! and " subunits (reviewed in 
Olsen and Sieghart 2009). Alpha 1 (!1), !2, !3 and !5 subunits render 
receptors sensitive to benzodiazepines. However, !4 and !6 subunits contain 
a histidine residue instead of arginine residue at a position participating in 
allosteric benzodiazepine binding site. This renders the receptor with these 
subunits insensitive to benzodiazepine binding (Wieland et al. 1992). 
Benzodiazepine binding sites are located throughout the brain in the 
hippocampus, thalamic areas, cerebellum, cortical structures and mesolimbic 
system (Braestrup and Squires 1982). 
Morphine and benzodiazepines each target mesolimbic DA system in the 
VTA in a slightly different manner. Morphine preferentially binds to µ-
receptors by inhibiting GABAergic interneurons, which in turn causes 
decreased modulatory inhibition of DA neurons (Johnson and North 1992), 
thus the net effect being excitation of DA neurons by the mechanism of 
disinhibition. This evokes increased DA release at the target areas of VTA DA 
neurons, most prominently in the NAc (Di Chiara and Imperato 1988). 
Benzodiazepines also activate VTA DA neurons via disinhibition by binding to 
the !1-subunit containing GABAA receptors in the interneurons (Tan et al. 
2010). 
One of the early and seemingly common plastic mechanism elicited by 
many drugs of abuse, thus also morphine and benzodiazepines, is the synaptic 
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potentiation in the VTA DA neurons (Ungless et al. 2001; Heikkinen et al. 
2009). This LTP is observed as early as two hours after the drug administration 
and lasting beyond the actual presence of drugs and their metabolites in the 
brain. LTP is dependent on NMDA receptors, suggesting a similar underlying 
mechanism between VTA DA plasticity and the classical hippocampal LTP 
(Ungless et al. 2001; Heikkinen et al. 2009). However, drugs of abuse neither 
evoke LTP in the hippocampus nor at excitatory synapses on the VTA 
GABAergic cells. The specificity of this plastic event is further substantiated by 
the finding that other centrally acting drugs fluoxetine and carbamazepine do 
not cause the observed potentiation (Saal et al. 2003). These modifications 
seem to disagree with the premise that addiction is a chronic disease, since 
VTA DA neuron LTP was observable only for a week, even after the drug was 
repeatedly administered (Borgland et al. 2004). Therefore, other correlates of 
addiction-inducing plasticity must emerge. 
 
2.4 GLUTAMATE, AN EXCITATORY 
NEUROTRANSMITTER 
Neurotransmitter glutamate, released from the presynaptic neuron, mediates an 
excitatory response through its receptors thus leading to the activation of the 
postsynaptic neuron. Glutamate is found throughout the CNS and acts as the 
principal excitatory neurotransmitter in many neuronal networks (Fonnum 
1984). 
Apart from the role in plain excitatory neurotransmission, the glutamatergic 
system provides a platform for an organism to adapt to various dynamic 
situations. Neuronal adaptation, driven by modifications in the properties of 
the glutamate system, enables functions like learning and memory. 
Glutamatergic adaptations can lead to changes in the nervous system lasting 
from seconds to lifetime, thus suggesting a complex system. 
 
2.5 CELLULAR TURNOVER OF GLUTAMATE 
2.5.1 SYNTHESIS 
 
Mismatch applies to glutamate synthesis and the site of its release as a 
transmitter in neurons. Although glutamate is released from neurons, most 
neurons contain no machinery to fully synthesise it from the precursor glucose 
(Hertz et al. 1999). More specifically, to utilise glucose in this process, an 
enzyme pyruvate carboxylase is required, which is expressed in glial cells of 
astrocyte type, but not in neurons (Yu et al. 1983). Astrocytes feed neurons 
with an amino acid glutamine (Albrecht et al. 2007) that has been synthesized 
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from glucose. The neuronal expression of enzyme phosphate-activated 
glutaminase subsequently enables neurons to transform glutamine to glutamate 
(Danbolt 2001). However, this classical view of neuronal inability to de novo 
synthesise glutamate has been challenged by providing evidence of neuronal 
puryvate carboxylase activity (Hassel and Bråthe 2000). Furthermore, 
microglial cells have also been shown to produce glutamate (Patrizio and Levi 
1994). 
Glutamate is also a precursor for the main inhibitory neurotransmitter 
GABA (see above). This transformation occurs by the use of glutamic acid 
decarboxylase (GAD) in GABAergic neurons (Martin and Rimvall 1993). 
Thus, interestingly, the principal excitatory and inhibitory neurotransmitter 
systems are closely interconnected at the metabolic level. 
 
 
 
 
 
Figure 2. Glutamate-glutamine cycle. Glutamate is released from the vesicles to 
the synaptic cleft by exocytosis, followed by uptake to astrocytes by excitatory 
amino acid transporters. In astrocytes, enzyme glutamine synthetase converts 
glutamate to glutamine, which is transported to the extracellular space and finally 
to presynaptic neuron by system N/A transporters. In the presynaptic neuron 
glutamine is converted back to glutamate by enzyme phosphate-activated 
glutaminase. Glutamate is packed to presynaptic vesicles by vesicular glutamate 
transporter. Abbreviations: EAAT, excitatory amino acid transporter; Gln, 
glutamine; Glu, glutamate; GluRs, glutamate receptors; GS, glutamine synthetase; 
PAG, phosphate-activated glutaminase; SNAT, system N/A transporter; VGLUT, 
vesicular glutamate transporter. 
Glu
GluRs
Postsynaptic neuron
Presynaptic neuron
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2.5.2 RELEASE 
 
Figure 2 represents the route of glutamate from release, to uptake, and finally  
to vesicle loading. Continuous release of glutamate occurs from presynaptic 
neurons to the synaptic cleft, which is demonstrated by the accumulation of 
extracellular glutamate due to the blockade of uptake capability (Jabaudon et al. 
1999). Glutamate release typically occurs by vesicular exocytosis in response to 
a rise in intracellular calcium (Bollmann et al. 2000). These vesicles are loaded 
with glutamate by vesicular glutamate transporters (VGLUT1-3) that are 
expressed in the presynaptic terminal on the cytoplasmic vesicles. VGLUT1 
and VGLUT2 are expressed in the cortical and subcortical regions, while 
VGLUT3 is found in the raphe serotonergic, striatal cholinergic and cerebellar 
and hippocampal GABAergic neurons (Ni et al. 1994; Aihara et al. 2000; 
Fremeau et al. 2002). An estimate of the number of glutamate molecules per 
each vesicle has been proposed based on a combination of methods of 
electron microscopy and immunohistochemistry, although without a resolution 
of a single vesicle. Vesicle size is subject to change, and thus an approximation 
from 400 to 4000 molecules has been suggested (Shupliakov et al. 1992; 
Schikorski and Stevens 1997). Also, reversed transporter activity, that releases 
instead of removing glutamate from the synapse, has been speculated as a 
mechanism (Rossi et al. 2000), although this may only exist in pathological, 
excitotoxic conditions triggered by abnormal cell membrane ion gradients. 
Two types of glutamate release take place in neuronal communication. 
These being evoked, action-potential-driven, and spontaneous release that 
gives rise to so called miniature excitatory postsynaptic potentials. Several 
features differentiate these types of release. First, release rate of vesicles is 
highly variable (>100 Hz and 0.02 Hz, for evoked and spontaneous release, 
respectively), as determined by optical dye-loading (Murthy and Stephens 1999) 
and electrophysiological (Geppert et al. 1994) methods. Second, evoked and 
spontaneously released glutamate has been suggested to activate different 
postsynaptic receptor pool (Atasoy et al. 2008). Third, the physiological role of 
spontaneously released glutamate may deviate from the evoked one by, for 
example, stabilising the neuronal connections due to fostering of dendritic 
spine morphology in an AMPA receptor-mediated way (McKinney et al. 1999). 
Glutamate is co-released with other neurotransmitters in native neuronal 
networks (for various neurotransmitters co-released with glutamate, see El 
Mestikawy et al. 2011). This co-release further supports the role of glutamate as 
the main excitatory neurotransmitter in the CNS. Co-release is based on the 
notion that expression of VGLUT1-3 is also localised in areas other than 
principal glutamate neurons (see above). This implies that VGLUTs cannot be 
used as specific markers for glutamatergic neurons exclusively, but that the 
possible expression for other transmitters has to be confirmed. 
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2.5.3 UPTAKE 
 
Once released, glutamate is quickly removed from the synapses for three main 
reasons. First, excess glutamate is neurotoxic due to its excitatory nature. 
Excitotoxicity is based on glutamate-initiated cascade of events, that can lead 
to neuronal death (Lau and Tymianski 2010). Thus, the main excitatory 
neurotransmitter, critical it is to brain activity, also possesses great potential to 
harm the brain. Second, in order to maintain a good signal-to-noise ratio of 
glutamate neurotransmission, the synaptic cleft must be cleaned from 
glutamate. Third, recycling of glutamate reduces the need for de novo synthesis 
(see above). 
Molecular cloning has identified five subtypes of glutamate transporters that 
are responsible for the uptake of glutamate from the synapse. These have been 
named excitatory amino acid transporters (EAAT1-5), and an alternative 
nomenclature exists for the three first: glutamate-aspartate transporter, 
glutamate transporter and excitatory amino acid carrier, for EAAT1, EAAT2 
and EAAT3, respectively (for review, see Slotboom et al. 1999). EAAT1 and 
EAAT2 mainly account for the uptake in the CNS with the most extensive 
expression in the CNS (Lehre et al. 1995). These transporters have been largely 
localised to astroglia, but their neuronal expression has been debated (for 
review, see Danbolt 2001). The other transporters are mainly neuronal, with 
EAAT3 being expressed in the hippocampus, cerebellum and basal ganglia 
(Conti et al. 1998), EAAT4 in cerebellar Purkinje cells (Yamada et al. 1996), and 
EAAT5 in retinal bipolar cells (Bringmann et al. 2009). Thus, a site-specific 
mismatch largely applies to glutamate release and uptake. 
When glutamate is taken up by astrocytes, it is not directly re-released to the 
extracellular space (see above). Instead, glial enzyme glutamine synthetase 
converts glutamate to glutamine (Albrecht et al. 2007). This process closes the 
circle of the two amino acids glutamate and glutamine, and is named the 
glutamate-glutamine cycle (see Figure 2). The importance of glutamate 
transporters in the cellular turnover of glutamate has led to development of 
various ligands to pharmacologically modulate glutamate uptake (Shigeri et al. 
2004). 
2.6 GLUTAMATE RECEPTORS 
Glutamate receptors are proteins binding glutamate and mediating the 
excitatory synaptic transmission in the CNS. The receptors fall into two main 
categories, ionotropic and metabotropic receptors (reviewed in: Traynelis et al. 
2010; Niswender and Conn 2010; Granger et al. 2011). Ionotropic receptors are 
comprised of four variable subunit proteins forming a channel that is 
permeable to ions, which mediate the glutamate signal. These receptors 
mediate the fast component of the glutamatergic transmission in a millisecond 
scale. Metabotropic receptors are proteins that pass the glutamate signal using 
G-protein coupling and mediate slower transmission modulating the 
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glutamatergic tone. Both receptor classes are localised in the neurons and glial 
cells. The classification of glutamate receptors is based both on pharmacology 
and molecular biology. Nomenclature of glutamate receptors is displayed in 
Table 1. 
Glutamate receptors can be targeted with various pharmacological ligands 
that alter the properties and function of the receptors. Understanding the 
crucial role of glutamate and its receptors in CNS, it is surprising how few of 
the glutamatergic ligands have reached the status of a therapeutic drug in 
medical practice. However, a great many of the ligands have had an important 
role as a research tool in biological sciences. Also see below for AMPA 
receptor pharmacology. 
2.6.1 AMPA RECEPTORS 
 
AMPA receptors have been named after !-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid, a synthetic pharmacological ligand that exerts an 
agonistic effect on these receptors (Honore et al. 1982). These receptors 
mediate the fast glutamate signal. See chapter 2.7 for a more detailed review of 
AMPA receptor properties. 
2.6.2 NMDA RECEPTORS 
 
NMDA receptors have been named after N-methyl-D-aspartate, which is a 
synthetic ligand having agonistic effect on NMDA receptors (Curtis and 
Watkins 1960). NMDA receptors are comprised of 14 possible subunits 
including variants from alternative splicing, of which two GluN1 subunits are 
required together with either two GluN2 subunits or a combination of GluN2 
and GluN3 subunits (Monyer et al. 1992). The outcome is thus a four-subunit 
tetramer with a cation-permeable pore inside the complex (Laube et al. 1998). 
The opening of the channel pore requires three events to occur. This includes 
binding of glutamate to GluN2 subunits, glycine acting as a co-agonist to 
GluN1 subunits (Johnson and Ascher 1987), and membrane depolarisation to 
remove the voltage-dependent physical Mg2+-block from the intracellular site 
(Mayer et al. 1984). All of these requirements are modified upon the subunit 
composition of the receptor to yield variable binding of the ligands and to 
affect the sensitivity of the voltage-dependency in removing the Mg2+ block 
(Kuryatov et al. 1994; Kutsuwada et al. 1994; Cull-Candy et al. 2001; Clarke and 
Johnson 2006). The carriers of the electrical current through NMDA receptor 
are ions Na+, Ca2+ and K+ (MacDermott et al. 1986; Mayer and Westbrook 
1987). 
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NMDA receptors are located ubiquitously throughout the CNS, but 
regional distribution of different subtypes exists that also is regulated during 
the development (Monyer et al. 1994). Subcellular localisation studies imply 
that NMDA receptors are found in both post and presynaptic sites (Pinheiro 
and Mulle 2008).  
 25 
TABLE 1. GLUTAMATE RECEPTORS 
     
RECEPTOR 
FAMILY 
SUBUNIT  
NAME 
PREVIOUS NAMES HUMAN GENE 
NAME 
HUMAN CHROMOSOMAL 
LOCATION 
 
IONOTROPIC RECEPTORS 
AMPA GluA1 GluR-A, GluR1 GRIA1 5q31.1 
 GluA2 GluR-B, GluR2 GRIA2 4q32–q33 
 GluA3 GluR-C, GluR3 GRIA3 Xq25–q26 
 GluA4 GluR-D, GluR4 GRIA4 11q22 
     
NMDA GluN1 NR1 GRIN1 9q34.3 
 GluN2A NR2A GRIN2A 16p13.2 
 GluN2B NR2B GRIN2B 12p12 
 GluN2C NR2C GRIN2C 17q25 
 GluN2D NR2D GRIN2D 19q13.1 
 GluN3A  GRIN3A 9q31.1 
 GluN3B  GRIN3B 19p13.3 
     
KAINATE GluK1 GluR5 GRIK1 21q22.11 
 GluK2 GluR6 GRIK2 6q16.3–q21 
 GluK3 GluR6 GRIK3 1p34–p33 
 GluK4 KA1 GRIK4 11q22.3 
 GluK5 KA2 GRIK5 19q13.2 
     
ORPHAN GluD1 GluR!1 GRID1 10q22 
 GluD2 GluR!2 GRID2 4q22 
     
METABOTROPIC RECEPTORS 
GROUP I mGluR1  GRM1 6q24 
 mGluR5  GRM5 11q14.3 
     
GROUP II mGluR2  GRM2 3p21.2 
 mGluR3  GRM3 7q21.1 
     
GROUP III mGluR4  GRM4 6p21.3 
 mGluR6  GRM6 5q35 
 mGluR7  GRM7 3p26 
 mGluR8  GRM8 7q31.3 
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NMDA receptors, as well as AMPA and kainate receptors, are also located 
in several peripheral tissues. For example, pancreatic islet cells and bone tissue 
osteoclasts express them (Inagaki et al. 1995; Chenu et al. 1998). 
The physiological role of NMDA receptors for neuronal plasticity is critical. 
In response to depolarisation of the membrane, the removal of Mg2+ block 
enables Ca2+ flow through the receptor leading to subsequent calcium-initiated 
effects that govern LTP of the synapse (for review, see Blundon and 
Zakharenko 2008). This process is seen as a putative molecular correlate of 
memory (Bliss and Lømo 1973). The NMDA receptor is an “observer” of 
temporally concomitant stimuli (Bliss and Collingridge 1993), and thus NMDA 
receptor has been named a “coincidence detector” of the CNS. Due to the 
Mg2+ block, a rather high threshold in membrane potential must be overcome 
to facilitate the glutamate-induced activation of NMDA receptors. 
Consequently, the basal synaptic transmission is not mediated by NMDA but 
AMPA receptors, in which no such depolarisation-dependent block exist 
(Collingridge et al. 1983). Furthermore, NMDA and AMPA receptors work 
together in neurotransmission such that the activation of AMPA receptors 
leads to sufficient membrane depolarisation which also finally activates NMDA 
receptors (Petralia and Wenthold 2008). 
2.6.3 KAINATE RECEPTORS 
 
Kainate or kainic acid is a molecule derived from the algae Digenea simplex 
which binds to, and produces an agonistic effect on kainate receptors (London 
and Coyle 1979). Five kainate receptor subunits have been cloned (Bettler et al. 
1990; Werner et al. 1991; Egebjerg et al. 1991; Herb et al. 1992; Bettler et al. 
1992), and splice variants have been found, too (for review, see Lerma 2003). 
GluK1-3 can assembly as homomers or heteromers, but GluK4 and GluK5 
only form functional receptors when compiled with GluK1-3 subunits (for 
review, see Traynelis et al. 2010). The binding affinity of kainate is higher in 
cells transfected with GluK4 or GluK5 subunits compared to GluK1-3 
subunits (Werner et al. 1991; Herb et al. 1992). The kainate receptor, when 
activated, enables a flux of Na+ and K+ ions to pass through its channel 
(reviewed in: Traynelis et al. 2010). 
Kainate receptors are expressed throughout the CNS, with GluK2/GluK5 
heteromeric receptors being the most common subtype (Ball et al. 2010). 
Determination of the subcellular location of kainate receptors has been 
problematic due to the lack of selective antibodies for immunohistochemical 
studies needed to perform successive electron microscopy. However, both pre- 
and postsynaptic localisations have been suggested based on functional studies 
(Lerma 2003). 
Physiological importance of kainate receptors is a modulatory one: Kainate 
receptors bidirectionally regulate glutamate release as presynaptic autoreceptors 
(Kullmann 2001). Although glutamate levels at the synapse are rather low due 
to efficient uptake mechanisms (see above), kainate receptors detect ambient 
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glutamate concentrations and thus constantly regulate glutamate release (Lauri 
et al. 2005). Perhaps this feature is counterbalanced by the fast desensitisation 
of the kainate receptors seen in electrophysiological observations, at least in 
the hippocampal neurons (Patneau et al. 1993). While NMDA and AMPA 
receptors have an established role in formation and expression of LTP in 
neuronal communication, kainate receptors have not been suggested a similar 
direct part on LTP (Jane et al. 2009). However, recent studies implicate that 
kainate receptors are also involved in strengthening of the synaptic 
transmission (Bortolotto et al. 1999), as a regulatory type action (Lauri et al. 
2001). Much of the work in clarifying the roles of kainate receptors in the 
functions of the CNS have been put forward by pharmacology, as receptor-
specific ligands have become available, and been studied in the developing 
hippocampus (Jane et al. 2009). 
2.6.4 ORPHAN RECEPTORS 
 
Orphan receptors include GluD1 and GluD2-subunit containing ion channels, 
which have been cloned (Yamazaki et al. 1992; Lomeli et al. 1993). These 
subunits show approximately 20% sequence homology to other ionotropic 
glutamate receptor subunits. GluD1 subunit is expressed in the hippocampus 
at low levels, while GluD2 subunit localises to cerebellar Purkinje cells (Lomeli 
et al. 1993). However, in recombinant expression systems, the receptors 
composed of these subunits neither bind glutamate nor are activated by 
glutamate (Yamazaki et al. 1992; Lomeli et al. 1993). D-serine binds to 
recombinant GluD2 receptors, but does not activate the receptor (Naur et al. 
2007). Thus, these receptors might not represent a functional role as ion 
channels. Perhaps a more plausible account for the orphan receptors might be 
in the regulation of AMPA receptor subunits. This has been suggested by data 
from GluD2-deficient mice (Yamasaki et al. 2011) which show reduced 
mismatch in the number of AMPA receptors between two types of Purkinje 
cell synapses. These data can also assist in explaining deficient motor 
coordination and impaired cerebellar synapse formation and LTD seen in this 
mouse line (Kashiwabuchi et al. 1995). 
2.6.5 METABOTROPIC GLUTAMATE RECEPTORS 
 
Metabotropic glutamate receptors (mGluRs) belong to the superfamily of G-
protein-coupled receptors (GPCRs) and to the subfamily of class C receptors. 
These receptors, when activated by glutamate, propagate the signal using G-
protein interaction followed by activation or inhibition of subsequent second 
messenger systems. Metabotropic glutamate receptors are divided into three 
groups based on ligand selectivity, G-protein coupling and amino acid 
sequence. Group I includes mGluR1 and mGluR5, group II includes mGluR2 
and mGluR3, and group III includes mGluR4, mGluR6, mGluR7 and 
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mGluR8. Altogether 8 genes that encode the mGluRs have been identified, 
several splice variants exist that can further increase the heterogeneity of the 
mGluR system. (reviewed in Kew and Kemp 2005). 
Metabotropic glutamate receptors are expressed in dimers, presumably 
requiring glutamate binding to both receptor units (Suzuki et al. 2004; Kniazeff 
et al. 2004; Kammermaier and Yun 2005), although these studies only cover 
mGluR1 homomeric assembly. Signal transduction is continued by recruiting 
the G-protein system. Group I receptors couple to Gq protein to activate 
phospholipase C, resulting in the production of the second messenger, 
inositol-1,4,5-triphosphate. Group II and group III receptors couple to Gi/o 
proteins leading to inhibition of adenylyl cyclase and the decrease of the 
second messenger cyclic adenosine monophosphate. However, in addition to 
these, a multitude of pathways can be activated by both receptor groups thus 
increasing the complexity of the system (reviewed in Niewander and Conn 
2010). 
The majority of mGluRs are widely expressed in the CNS, with only 
mGluR6 being restricted to the retina (Nakajima et al. 1993). Localisation to 
both neurons and glia exists, and both pre- and postsynaptic subcellular 
localisation has been identified (Pinheiro and Mulle 2008). 
Generally, group I mGluRs are located postsynaptically (Lujan et al. 1996) 
and group II and III mGluRs presynaptically. When postsynaptic group I 
receptors are activated, the outcome is depolarisation of the postsynaptic 
membrane and thus an excitatory response. Presynaptic group II and III 
receptors, however, inhibit glutamate release. Group I receptors are involved 
in LTP and LTD induction, either as direct inductors or facilitators (Anwyl 
1999). In various brain regions, mGlu-mediated LTD provides another type of 
bidirectional synaptic plasticity that is not NMDA receptor-dependent 
(Lüscher and Huber 2010), although in some brain region like amygdala both 
sources of activation are required for LTD (Wang and Gean 1999). In 
addition, both group II and group III receptors are involved in LTD (Pinheiro 
and Mulle 2008). Group II receptors accompany the communication between 
neurons and glia (Bruno et al. 1999), and can efficiently reduce the glutamate 
excitation to postsynaptic neurons. Similar role has been detected for mGlu7 
receptors, which possess low affinity for glutamate and are possibly sensors of 
excess glutamate (Niewander and Conn 2010). 
 
2.7 AMPA RECEPTORS AND THEIR PROPERTIES 
AMPA receptors form a cation channel that is permeable to Na+ and K+, and 
depending on subunit composition of the receptor, also to Ca2+ ions. Ion flux 
through the receptor depolarises the postsynaptic membrane, leading to 
excitatory postsynaptic potential (EPSP). Many properties of AMPA receptors 
establish mechanisms for adaptational modifications that can underlie changes 
in behaviour. 
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2.7.1 AMPA RECEPTOR SUBUNITS AND TOPOLOGY 
 
AMPA receptors are tetramers constructed out of four distinct subunits, 
GluA1 to GluA4, which can be assembled in either homomers or heteromers 
(Hollmann et al. 1989; Keinänen et al. 1990). The molecular structure is similar 
between different subunits, and the subunits show approximately 70% 
homology in sequence. Each subunit consists of approximately 900 amino 
acids and has a molecular weight of 105 kDa. Figure 3 depicts AMPA receptor 
subunit structure. 
Four main domains can be identified in each subunit. The amino-terminal 
domain, ligand binding domain, transmembrane domain and carboxyl-terminal 
domain (for review, see Traynelis et al. 2010). The amino-terminal domain is 
extracellularly located, has a large lobe consisting almost half of the subunits 
amino acids and that has been difficult to find a functional significance for. 
However, using molecular biological techniques, various mutations to the 
amino acid sequence have been made, enabling a closer study of this domain. 
These data suggest that amino-terminal domain is not necessary for receptor 
assembly and general function of the ion channel, but is needed for regulatory 
roles such as binding of extracellular proteins N-cadherin and pentraxins 
(O’Brien et al. 1999). The ligand binding domain, that is also located 
extracellularly, consists of two lobes, S1 and S2. These lobes create a clamshell-
like binding pocket for glutamate. When bound, glutamate interacts with its 
receptor leading to a conformational change in the ligand binding domain, 
changing the channel structure and opening it (Erreger et al. 2004). 
Transmembrane domains TM1-TM4 of each of the four subunits form the ion 
channel of the receptor. TM2 differs from the others as it forms an 
intracellular hairpin loop thus not fully traversing the cell membrane (Molnar et 
al. 1994). Finally, the intracellular carboxyl-terminal domain contains 
interaction sites for intracellular proteins that function in trafficking of the 
AMPA receptors, an important step in activity-dependent modifications 
leading to LTP or LTD, and possibly in other forms of adaptation (see for 
review Henley 2003). 
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Figure 3. Topology of the AMPA receptor subunit. The four basic domains of the 
AMPA receptor subunit are shown. N-terminal domain comprises of nearly half of 
the amino acids of the subunit, but lacks a clear functional role. The ligand-binding 
domain consists of two lobes, S1 and S2, which form a binding pocket for 
glutamate. The binding of glutamate causes a conformational change in the 
transmembrane domain structure leading to opening of the ion channel. Carboxyl-
terminal domain includes several locations for post-translational regulation such as 
phosphorylation. Alternative splicing occurs at flip/flop site where one of the two 
alternative exons is selected for the final mRNA. At the RNA editing sites the gene-
encoded residue is changed post-transcriptionally to another one (R to G and Q to 
R). Abbreviations: Glu, glutamate; S1 and S2, ligand-binding domain lobes 1 and 
2; TM1-4, transmembrane domains 1-4. “In” and “out” represent intracellular and 
extracellular spaces, respectively. 
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2.7.2 PROTEIN SYNTHESIS  
 
Four genes encode AMPA receptor subunit proteins, GRIA1-4 and gria1-4, for 
human and mouse genome, respectively. Each of the genes localises to a 
different chromosome (Collingridge et al. 2009). Subunits are produced and 
assembled in endoplasmic reticulum as dimers of dimers, and then a highly 
complex trafficking machinery moves them to the intracellular and synaptic 
sites (see below). Also, mRNA can be trafficked out to the dendritic regions, 
where a local machinery including polyribosomes, translational system and 
Golgi apparatus is expressed. The expression level of each subunit in vitro 
determines the composition of subunits (stoichiometry) in each receptor 
(Palmer et al. 2005). It remains to be determined how this occurs in vivo. 
However, RNA editing (see below) controls assembly to favor GluA2 as the 
most common partner (Greger et al. 2002). Transcription of the subunit 
mRNAs is regulated by various transcription factors, such as nuclear factor $B, 
cAMP response element, restriction element-1 and specific transcription 
factor-1. The gene expression of the subunits is dependent on neuronal 
activity, with AMPA receptors playing a role in neuronal signalling cascades 
regulating gene expression (Wang et al. 2007). 
2.7.3 POST-TRANSCRIPTIONAL AND POST-
TRANSLATIONAL REGULATION 
 
During the protein synthesis of AMPA receptor subunits, the transcribed RNA 
can be modified to yield various forms of proteins that have differing 
functions. Furthermore, while the protein synthesis of AMPA receptor 
subunits takes place in the endoplasmic reticulum, the proteins undergo later 
modifications of phosphorylation, glycosylation, palmitoylation and 
ubiquitination in the Golgi apparatus. Both types of regulation have been 
shown a critical role in the adaptative changes that involve AMPA receptors 
(for review, see Henley et al. 2011). 
2.7.3.1 Post-transcriptional regulation 
 
Alternative splicing generates two isoforms, “flip” and “flop”, of AMPA 
receptor subunits GluA1-GluA4 (Sommer et al. 1990). This modification is 
located extracellularly prior to TM4 (from the N-terminal) and it covers a 
region of 115 base pairs. The expression of these variants is dependent on the 
developmental stage. Flip isoform dominates during the embryonic phase, but 
progressively more flop isoform emerge before replacing the flip isoform at 
postnatal day 14 in the rat brain (Monyer et al. 1991). Flip isoform renders 
AMPA receptors less prone to desensitisation compared to flop isoform, but 
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affinity to AMPA remains unchanged (Mosbacher et al. 1994; Arvola and 
Keinänen 1996). 
Another site of alternation in splicing produces the second type of 
isoforms, “short” and “long”, in GluA1, GluA2 and GluA4 subunits with 
GluA3 lacking the specific site required for splicing to occur (Gallo et al. 1992). 
The modification site is located near C-terminal, intracellularly. GluA1 appears 
only in the long form, with GluA2 and GluA4 mainly in the short form 
(Köhler et al. 1994). Proteins interacting with AMPA receptors (see below) 
have their binding sites at the C-terminal domain and consequently alternative 
splicing generates different environment for these interactions (Dev et al. 
1999). 
RNA undergoes another type of post-transcriptional modification leading 
to changes in amino acid codons and thus amino acids themselves in the 
subunit proteins. RNA editing takes place at two sites and its occurrence is 
dependent on receptor subunit. In GluA2, adenosine deaminase acting on 
RNA (ADAR2) changes the codon for glutamine (CAG) to arginine (CIG, 
coding for arginine CGG) leading to change (Q/R) that is located in the TM2 
(Higuchi et al. 2000). Arginine possess electrochemically positive motifs, and 
when inserted into the channel-forming region of AMPA receptor, results in 
receptors impermeable to Ca2+ (Sommer et al. 1991). Since the GluA2 subunit 
is predominantly found in the edited form and participates in most of the 
AMPA receptors assemblies, the usual AMPA receptor is impermeable to Ca2+. 
The editing is, however, developmentally regulated leading to unedited GluA2 
and thus to Ca2+-permeable receptors during the embryonic phase (Kawahara 
et al. 2003). RNA editing at the second site located near the flip/flop splicing 
site results in a change from arginine to glycine (R/G) in the GluA2-GluA4 
subunits (Lomeli et al. 1994). This editing modifies receptors desensitisation 
and resensitisation. 
The variants of postranscriptional regulation taking place during 
development preferentially lead to receptors which contain properties that 
strengthen the glutamatergic neurotransmission. As discussed above, this can 
be achieved by decreasing desensitisation (alternative splicing and RNA editing 
at R/G), or by increasing Ca2+-permeability (RNA editing at Q/R). The 
physiological significance of developmental promotion of the glutamatergic 
tone is not entirely known, but during development intense neurogenesis 
occurs, a process shown to be regulated by unedited GluA2-containing AMPA 
receptors (Whitney et al. 2008). Beyond the developmental phase, these 
activating processes may become unnecessary or also their role diminishes. 
Indeed, during adulthood, excessive Ca2+-permeability of AMPA receptors 
causes problems in behaviour (Jia et al. 1996; Gerlai et al. 1998; Higuchi et al. 
2000. In summary, AMPA receptors are involved in adaptational processes as 
early as the first stages of development. 
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2.7.3.2 Post-translational regulation 
 
Phosphorylation modifies receptor subunits by the addition of a phosphate 
group to certain sites at the C-terminal domain. AMPA receptor subunits have 
their own respective phosphorylation features. GluA1 subunit is 
phosphorylated by protein kinase C and Ca2+/calmodulin-dependent protein 
kinase II at serine 831, leading to increases in AMPA receptor currents. GluA1 
is also phosphorylated by protein kinase A at serine 845 (reviewed in Palmer et 
al. 2005) resulting in potentiation of homomeric peak currents. GluA2 is 
phosphorylated by protein kinase C at serine 880, which facilitates 
internalisation of receptors from the synaptic membrane. GluA3 is 
phosphorylated at three sites, but no functional role has been suggested 
(reviewed in Traynelis et al. 2010). GluA4 is phosphorylated by protein kinase 
A at serine 842 leading to insertion of homomeric receptors to the synapses 
(Esteban et al. 2003). Regulation of phosphorylation is interconnected with 
synaptic activity so that phosphorylation of subunits modifies synaptic activity 
and vice versa. All of these phosphorylation processes, except for GluA3, are 
involved in LTP or LTD (reviewed in Lee 2006) through AMPA subunit 
surface expression (see below). 
Glycosylation, a process of attachement of a carbohydrate residue, takes 
place at all of the AMPA receptor subunits at two sites located extracellularly. 
This form of regulation modifies AMPA receptor properties by protecting 
them from proteolysis and also modulates receptor trafficking (for review, see 
Palmer et al. 2005). 
Palmitoylation, a process of fatty acid incorporation, takes place in all 
AMPA receptor subunits. Palmitoylation is required for correct AMPA 
receptor surface expression (Hayashi et al. 2005) through enabling interaction 
between AMPA receptors and their interacting proteins, in particular protein 
4.1 (Shen et al. 2000) (see below). 
Ubiquitination, a process of tagging ubiquitin to proteins, is involved in 
delivery of AMPA subunits to degradation (Schwartz et al. 2010). 
2.7.4 PERISYNAPTIC TRAFFICKING AND 
INTERACTING PROTEINS  
 
Once the AMPA subunits have been biosynthesised and assembled, they 
undergo trafficking to the synaptic membrane. The process of AMPA receptor 
turnover has been regarded as one of the mechanisms leading to LTP and 
LTD (for review, see Shepherd and Huganir 2007). The trafficking to synapses 
takes place using two different pathways in a subunit-specific manner, although 
a complete understanding of the trafficking machinery remains to be 
determined. A direct, exocytotic route involves the delivery of GluA2 subunits 
directly to the synapse. An indirect diffusion route involves preceding 
trafficking of GluA1 subunits to a more distal location before being finally 
moved to the postsynaptic density with association of synapse-associated 
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protein-97 (Hayashi et al. 2000; Passafaro et al. 2001; Shi et al. 2001). Activity-
dependency is also apparent in that GluA2 receptors display constitutive 
perisynaptic movement associated with protein interacting with C kinase 1 (Xia 
et al. 1999), whereas GluA1 receptors, possibly also homomeric ones, show 
movement in response to NMDA receptor activation and an elevation in 
intracellular Ca2+. This suggests that extrasynaptic AMPA receptors are mainly 
GluA1 subunit-containing, although this remains to be confirmed. Constitutive 
movement indicates that the turnover of AMPA receptors also includes a 
removal phase. In this process, GluA2-containing receptors undergo 
internalisation (Lee et al. 2004) which is based on interaction with N-
ethylmaleimide-sensitive factor (NSF). On the contrary, NSF participates to 
insertion of GluA2 subunits to the synaptic membrane by detaching GluA2 
from interacting with the protein interacting with C kinase 1 (PICK1); an 
interaction that stabilises AMPA receptors to the intracellular sites (Hanley et 
al. 2002). Stabilisation of AMPA receptor to the synaptic membrane, however, 
involves protein 4.1 (Shen et al. 2000) and transmembrane AMPA receptor 
regulatory proteins. These comprise a family of interacting proteins that not 
only direct receptor trafficking but also modulate the kinetics of the receptor 
ion channel. It has been suggested that the interactions occur on a specific site 
on the gaps between the subunits (Sobolevskiy et al. 2009). 
2.7.5 LOCALISATION 
 
AMPA receptors are expressed throughout the CNS with divergent levels 
across the brain regions. The distributional map of AMPA receptor expression 
has been determined by receptor autoradiographic (Monaghan et al. 1984), in 
situ hybridisation (Keinänen et al. 1990) and immunohistochemical (Petralia and 
Wenthold 1992) methods. Even though these methods measure receptors at 
different stages of protein synthesis (i.e. at the mRNA and at the protein level), 
overlapping results for the regional distribution have been gained. With the 
two latter techniques being capable of subunit level resolution, receptor 
subunit-specificity in the regional distribution has also been shown to occur. 
The most notable distinction to the other subunits is the very low level of 
GluA4 expression outside the cerebellum. In overall, the expression of the 
AMPA receptors in rodents is high in the hippocampal subregions (CA1, CA3 
and dentate gyrus), the cortical regions, the basal ganglia, the olfactory bulbs 
and the amygdala. 
AMPA receptors are localised in both neuronal and glial cells, although the 
expression takes place at lower level in the latter (Gallo and Ghiani 2000). 
Subcellular localisation of AMPA receptors indicates that 60-70% of the 
receptors are at intracellular sites, thus forming a reserve pool of receptors 
unless they possess an unknown duty distinct from the silent synapse theory 
(Lee et al. 2001). An extrasynaptic (Baude et al. 1994) and presynaptic (Pinheiro 
et al. 2003) subcellular localisations have also been suggested. 
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2.7.6 PHARMACOLOGY OF AMPA RECEPTORS 
 
Glutamate is the endogenous agonist for AMPA receptors, kainate and 
NMDA receptors. NMDA cannot activate AMPA receptors, and AMPA 
cannot activate NMDA receptors. Similar selectivity does not occur between 
AMPA and kainate receptors (for review, see Traynelis et al. 2010). Indeed, 
kainate is an agonist at AMPA receptors, and AMPA is a partial agonist at 
kainate receptors (Herb et al. 1992; Sakimura et al. 1992; Sommer et al. 1992). 
Despite the highly conserved ligand-binding domain, there are other structural 
differences between kainate and AMPA receptors, thus warranting the search 
for novel ligands to better discriminate between these receptors (Sobolevskiy et 
al. 2009) with some examples already suggested (Lauri et al. 2001).  
Antagonist pharmacology of AMPA receptors includes competitive, 
noncompetivite and uncompetitive ligands. Competitive, glutamate-site 
antagonists contain 6-cyano-2,3-dihydroxy-7-nitroquinoxaline (CNQX), 6,7-
dinitroquinoxa- line-2,3-dione (DNQX) and 2,3-dihydroxy-6-nitro-7-
sulfamoylbenzo(f)quinoxaline (NBQX), of which NBQX shows more 
selectivity for AMPA receptors over kainate receptors, and is lacking NMDA 
receptor glycine-site antagonism (Nikam and Kornberg 2001). Of these 
classical antagonists CNQX and DNQX act as partial agonists in the presence 
of transmembrane AMPA receptor regulatory proteins (TARPs). This implies 
that the results obtained in heterologous expression systems in vitro may deviate 
from those performed in native systems in vivo. Noncompetitive antagonist, 1-
(4-amino- phenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine 
(GYKI-53655), a negative allosteric modulator (see below), shows selectivity 
for AMPA receptors over kainate receptors (Gitto et al. 2003). Noncompetive, 
use-dependent, antagonists include polyamines argiotoxin, Joro spider toxin 
and spermine (Herlitze et al. 1993). All of these exhibit actions on AMPA 
receptors devoid of GluA2 subunits thereby making them important tools 
both in the study of Ca2+-permeable AMPA receptors and in the identification 
of the subunit composition of AMPA receptors (Laezza et al. 2006). Besides 
the orthosteric pharmacology targeting glutamate binding site, there is an 
emerging variety of allosteric AMPA receptor modulators. These can be either 
positive or negative modulators (see above), and offer an increased possibility 
for subtype-selectivity due to binding with other than the conserved agonist 
binding site. Among the positive modulators, there are various classes of 
substances, e.g. cyclothiazide, aniracetam and 1-(1,4-benzodioxan-6-
ylcarbonyl)piperidine (CX546), that differ in their potentiating-mechanims of 
action (reviewed in Traynelis et al. 2010). 
All these AMPA receptor ligands are unable to discriminate between the 
subtypes of AMPA receptors. Lack of subtype-selective AMPA receptor 
ligands complicates the more specific study of these receptors. However, 
genetically engineered transgenic mouse and cell lines have provided an 
alternative approach to dissect the AMPA receptor system in more detail (see 
below). 
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2.8 GLUA1 SUBUNIT-DEFICIENT MOUSE LINE 
GluA1 subunit-deficient mouse line (GluA1-KO mice) was generated by gene-
targeted mutation of murine gria1 gene (Zamanillo et al. 1999). The GluA1-KO 
mouse line has offered an alternative approach to study the role of the GluA1 
subunit in the absence of subunit-specific pharmacological ligands.  
2.8.1 BEHAVIOURAL PHENOTYPE 
 
Table 2 represents the behavioural findings and Table 3 the 
electrophysiological findings in GluA1-KO mouse line. There have been two 
main categories in the study of GluA1-KO mouse line. These include, different 
aspects of learning and memory, and the modelling of psychiatric diseases. 
This is not surprising as the wide variety of phenomena in these categories are 
highly dependent on plastic events. 
The immediate outcome of the deletion of gria1 gene per se was perhaps a 
result less expected. Indeed, it was found out that the GluA1-KO mice are 
grossly normal and viable despite missing one of the main molecular substrates 
of fast neuronal transmission (Zamanillo et al. 1999). Even more intriguing was 
then the finding that the hippocampal neurotransmission actually was largely 
normal, although subsequent studies have shown deficits in hippocampal, 
amygdaloid and spinal neurotransmission (Humeau et al. 2007; Romberg et al. 
2009).  
The basic behavioural characterisation of the GluA1-KO mouse line 
speficied the baseline behavioural phenotype as surprisingly normal 
(Bannerman et al. 2004). However, novelty-related hyperactive phenotype 
(Vekovischeva et al. 2001) emerged as a very robust one, and it was reproduced 
in many laboratories studying the mouse line (Mead and Stephens 2003; 
Cowen et al. 2003; Bannerman et al. 2004; Dong et al. 2003; Wiedholz et al. 
2008). Although a slight motor dysfunction in the behavioural level has been 
reported (Zhang et al. 2008), this does not seem to confound the locomotion 
of the GluA1-KO mouse line. This is evidenced in many locomotion-
dependent tasks showing similar or greater locomotor activity for GluA1-KO 
mice compared to wild-type (WT) control mice.  
In the processes of learning and memory, GluA1 subunit has been shown a 
distinctive role. GluA1-KO mice have intact spatial reference memory and 
disrupted spatial working memory (Zamanillo et al. 1999; Reisel et al. 2002). 
When these findings, repeated by different methods, are observed parallel with 
the non-existent hippocampal CA1 LTP in this mouse line, a dichotomy 
emerges between LTP and learning. However, the later studies of LTP in 
GluA1-KO mouse line have indicated that the absence of LTP is dependent 
on the electrophysiological parameters, and that there exists a GluA1-
independent form of LTP existent in GluA1-KO mouse line. 
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Reward learning also is very specifically disrupted in GluA1-KO mouse line. 
While pavlovian conditioning and the ability of the cue to increase 
instrumental actions to obtain the reward (pavlovian-to-instrumental transfer) 
were functional in the GluA1-KO mice, the cue itself was not able to act as a 
conditioned reinforcer and second-order schedules of reinforcement (Mead 
and Stephens 2003). However, place conditioning is functional in these mice, 
as evidenced by place preference induced by drug (morphine, cocaine) and 
non-drug rewarding stimuli (food). 
Aversive learning, studied as tone and contextual fear conditioning with 
foot-shock as an unconditioned stimulus, has been shown to be disrupted in 
GluA1-KO mice (Humeau et al. 2007). This deficit in fear conditioning was 
linked to absent amygdaloid LTP in both the subnuclei of the basolateral 
amygdala, basal and lateral nucleus. Interestingly, the basolateral amygdala is 
critically important for both reward and fear conditioning (Phillips and 
LeDoux 1992; Baxter and Murray 2002), but only the latter is disrupted in 
GluA1-KO mice. Thus, the conditioning processes mediated by the amygdala 
are complex ones, suggesting that there may be a GluA1-dependent 
dissociation between reward and aversive conditioning. 
The emotional behaviour of the GluA1-KO mouse line has also been 
studied in anxiety-related paradigms. Several studies have utilised variable 
methods, with almost as many different outcomes (Table 2). Thus, the anxiety-
related phenotype of the GluA1-KO mouse line has not been fully determined. 
The pathophysiological basis of various psychiatric diseases has been 
studied in GluA1-KO mice. In addiction-related symptomatology, GluA1 
subunit has been shown a critical role in mediating the conditioned 
reinforcement of reward, development of tolerance to drugs of abuse and 
finally in control-over behaviour evidenced as over-responding during 
extinction (Vekovischeva et al. 2001; Mead and Stephens 2003; Mead and 
Stephens 2007). As another core feature of addiction, relapse behaviour in 
response to cues previously associated with the drug reward, was not, however, 
modified in GluA1-KO mice. Stress is able to precipitate relapse behaviour, 
and while GluA1-KO mice show enhanced locomotor response to mild 
injection stress, no stress-induced relapse behaviour has been studied in this 
mouse line. However, VTA DA neurons show no cocaine-induced plasticity in 
GluA1-KO mice (Dong et al. 2004), a finding that might be linked to many of 
the behavioural phenotypes listed above. 
GluA1-KO mouse line has been postulated to show various aspects of 
symptoms related to schizophrenia and bipolar disorder. Locomotor 
hyperactivity in response to novelty and mild stress, deficient prepulse 
inhibition and impaired working memory all represent symptoms found in 
these disorders (World Health Organization 1999). Additionally, depression-
like phenotype has been suggested based on increased learned helplessness. 
However, decreased immobilisation detected in forced swim and tail 
suspension tests directs to an opposite direction, thus indicating a complex 
behavioural phenotype (Chourbaji et al. 2008). 
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Table 4 represents the neurochemical findings of GluA1-KO mouse line. 
Deletion of the GluA1 subunit from the mouse proteome provides an 
indication of the importance of subunit partnerships in the trafficking of 
neurotransmitter receptor subunits. While only the GluA1 subunit is absent, 
both the expression and the localisation of GluA2 subunit critically change so 
that less GluA2 is trafficked to the dendritic cell membranes while more of it 
stays in the somata (Zamanillo et al. 1999; Mead and Stephens 2003). 
A decade after the generation of the GluA1-KO mouse line a whole 
genome expression profile was performed from the hippocampal tissue (Zhou 
et al. 2009). A total of 38 genes were found to be regulated more than 30%, 
with main part of these related to calcium signalling. Other studies have 
addressed calcium permeability in the absence of GluA1 subunit using cobalt 
loading in spinal cord slices ex vivo, finding decreased permeability in laminae 
I/II and unchanged permeability in laminae III/IV (Hartmann et al. 2004). 
Thus, deletion of GluA1 subunit and consequently the homomeric calcium-
permeable channels results in calcium-related compensatory changes in the 
hippocampus. 
The expression of IEGs c-fos and arc or their protein products were found to 
be increased in response to novelty hyperactivity and restraint stress in the 
hippocampus, and decreased in response to formalin-induced intraplantar 
inflammation in the spinal cord (Hartmann et al. 2004; Fumagalli et al. 2010). 
Maximal electroshock, however, failed to alter the expression of c-fos, zif268, c-
jun and RGS2 (Zamanillo et al. 1999). Restraint stress increased the expression 
of phosphorylation of Ca2+ ! calmodulin-dependent protein kinase and 
decreased the phosphorylation of NMDA receptor subunits GluN1 and 
GluN2B, while the expression of these protein remained unmodified 
(Fumagalli et al. 2010). These results indicate that IEG signalling is functional 
in the absence of GluA1 subunit, and can be used as a marker of cellular 
activation (Kovacs 1998). These data also support the notion that GluA1-KO 
mice are supersensitive to rather small changes in the environmental status, 
while a powerful electroshock produces normal cellular activation. Thus, 
GluA1 subunit may be critical in mediating the changes of small magnitude, 
but not of large ones. 
Monoamine metabolism in GluA1-KO mice has been determined in 
various brain regions at the basal state and after multitude of manipulations. In 
the hippocampus, serotonin (5-HT) content was found to be decreased 
without any manipulations (Chourbaji et al. 2008). The clearance of exogenous 
microdialytically applied DA was decreased in GluA1-KO mice without 
alterations in DA release or dopamine transporter expression (Wiedholz et al. 
2008). 
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2.8.3 PHARMACOLOGICAL PHENOTYPE 
 
Table 5 represents the pharmacological findings of GluA1-KO mouse line. 
The main interest in the pharmacological study of GluA1 mouse line has been 
in drugs of abuse. Acute locomotor effects of the stimulants amphetamine, 
methylphenidate and cocaine produce variable outcomes in GluA1-KO mouse 
line. Locomotor-activating effect to amphetamine is either normal or increased 
(Vekovischeva et al. 2001; Fitzgerald et al. 2010), to methylphenidate the effect 
is increased (Fitzgerald et al. 2010), and to cocaine the effect is normal (Dong et 
al. 2004). 
Cocaine-induced sensitisation remains normal in GluA1-KO mice. 
However, amphetamine-induced sensitisation is increased when amphetamine 
is paired with the locomotor measurement context, but not when 
amphetamine is given in the home cage (Dong et al. 2004; Vekovischeva et al. 
2001). Repeated tolerance-inducing administration of morphine leads to 
decreased tolerance in GluA1-KO mice (Vekovischeva et al. 2001). Thus, 
deletion of GluA1 subunit impairs these forms of drug-induced plasticity that 
suggest the importance of GluA1 subunit-containing AMPA receptors in 
addiction-related symptomatology. 
Ethanol-induced behaviours are largely normal in GluA1-KO mice, with 
the exception that GluA1-KO mice were insensitive to ethanol-induced 
hypothermia (Cowen et al. 2003). 
Pharmacokinetics of morphine, ethanol and lithium were found to be 
unaltered in GluA1-KO mouse line. (Vekovischeva et al. 2001; Cowen et al. 
2003; Fitzgerald et al. 2010). 
2.8.4 OTHER GENETICALLY MODIFIED AMPA 
RECEPTOR MOUSE LINES 
 
GluA1(R/R) transgenic mice express a genetically modified GluA1 subunit 
with glutamine at the position 582 replaced by arginine, thus leading to 
receptors with very low channel conductance and no permeability to calcium 
(Vekovischeva et al. 2001, also see chapter 2.7.3.1). However, in the brain of 
these mice the GluA1 subunits are present and should successfully pair with 
GluA2 subunits, thus enabling membrane trafficking of GluA2 subunits. These 
mice have largely the same phenotype as the global GluA1-KO mice 
(Vekovischeva et al. 2001), suggesting that the phenotype of the GluA1-KO 
mouse line is due to the absence of functional GluA1 subunit-containing 
AMPA receptors. 
GluA2-deficient mice (GluA2-KO) have been generated in two laboratories 
(Jia et al. 1996; Shimshek et al. 2006). Deletion of GluA2 subunit results in a 
decrease in reproductive performance, maternal agonistic behaviour, 
explorative behaviour, motor coordination and in an impairment in reference 
memory in the water maze task (Gerlai et al. 1998; Shimshek et al. 2006). The 
findings indicating impaired reference memory are at odds with the 
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electrophysiological recordings displaying highly increased hippocampal and 
anterior cingulate cortical LTP (Jia et al. 1996; Toyoda et al. 2009). GluA2-KO 
mice have modified responses in addiction-related, plasticity-requiring 
behaviours as evidenced by impairments in pavlovian-to-instrumental transfer, 
conditioned approach, conditioned emotional response and food-conditioned 
place preference, although they have spared conditioned place preference for 
cocaine (Mead and Stephens 2003; Mead and Stephens 2005; Mead et al. 2006). 
Inflammatory pain-induced behavioural responses are mainly increased 
(Hartmann et al. 2004). In summary, the pattern of behavioural findings 
observed in GluA2-KO mouse line appears to be the opposite to that of 
GluA1-KO mouse line. 
GluA3-deficient mice (GluA3-KO) were generated and behaviourally 
characterized (Sanchis-Segura et al. 2006). The basic behavioural 
characterisation displayed no marked abnormalities in these mice, with the 
exception of slightly decreased novelty-induced locomotor activity and 
impairment in motor coordination. However, after an extinction/deprivation 
phase, these mice display both reduced number of ethanol-related lever-presses 
in response to the ethanol-paired cue and reduced ethanol drinking. However, 
self-administration neither in the voluntary ethanol drinking paradigm nor in 
the operant setting was changed. These data suggest a specific role for GluA3 
subunit in ethanol relapse behaviour, although reduced levels of expression for 
other AMPA receptor subunits were detected (Sanchis-Segura et al. 2006). 
Despite the fact that synaptic potentiation measured as LTP in cerebrocortical 
to lateral amygdala connections was absent in GluA3-KO mice, these mice 
showed both spared auditory and contextual fear conditioning behaviour 
(Humeau et al. 2007). In inflammation-induced pain the GluA3 subunit appears 
to be disposable (Hartmann et al. 2004). 
GluA4-deficient mice (GluA4-KO mice) have a specific hearing deficit 
related to sound localisation accompanied by impaired neurotransmission in 
calyx of Held synapses (Yang et al. 2011). GluA4-KO mice also display EEG-
recordable spontaneous absence seizures, that are sensitive to ethosuximide 
treatment (Paz et al. 2011).  
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3 AIMS OF THE STUDY 
This study was performed to determine the role of glutamate AMPA-type 
receptor GluA1 subunits in various behavioural and neurochemical adaptive 
events. To accomplish these goals, a mouse line deficient in GluA1 subunit 
was utilised, and exposed to a range of challenges that require neuronal 
adaptation. The specific aims can be summarised as: 
 
1. To perform a behavioural characterisation of the GluA1-KO mouse line 
 
2. To investigate the role of the GluA1 subunit in encounters that require 
agonistic behaviour 
 
3. To study the importance of GluA1 subunit in the processing of spatial 
novelty-related signals 
 
4. To study the role of the GluA1 subunit in the acute and subchronic effects 
of the benzodiazepine flurazepam 
 
5. To clarify the role of the GluA1 subunit in the morphine-induced state-
dependency 
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4 MATERIALS AND METHODS 
4.1 EXPERIMENTAL ANIMALS 
GluA1-KO mouse line was generated as described in Zamanillo et al. (1999). 
The male and female animals used in the experiments were produced by 
heterozygous breeding. Littermate WT mice were used as controls. The GluA1 
mouse line was backcrossed to the C57BL/6J strain throughout the study so 
that initially the number of backcrosses was 5 and eventually reaching over 10 
backcrosses. Genotype was determined using PCR from ear punch biopsy as 
described in Zamanillo et al. (1999). All experimental animal studies were 
approved by Southern Finland Provincial Government and Experimental 
Animal Committee of the University of Helsinki. 
4.2 BEHAVIOURAL METHODS 
The basic phenotypic profile (I) and the effects of flurazepam (III) were 
determined by SHIRPA behavioural screen which is based on visual 
observation of the animals (Rogers et al. 1999). 
Agonistic behaviour (I) was studied in various paradigms by observing 
mouse behaviour from video recordings using Ethograph software. In 
resident-intruder test, the test (resident) mouse was isolated for various time 
periods followed by encounter with a group-housed intruder mouse in the 
home cage of the test mouse. The same test was also performed in male mice 
after sexual activity and in female mice after isolation during the period of 
gestation. Interline agonistic behaviour was studied by exposing isolated 
GluA1-KO and WT mice to a neutral territory. Agonistic behaviour in a group 
was assessed within each genotype by placing isolated mice in a large arena. 
The test was repeated until all aggressive mice were identified.  
Anxiety behaviour (I) was studied in elevated plus-maze and light-dark 
exploration tests. Elevated plus-maze consisted of a central platform from 
which the mouse had access to two open arms and two closed arms. The maze 
was elevated to the height of 50 cm above floor level, and the closed arms 
offered mice a safe option to explore while the open arms were unprotected. 
The mice were placed in the central platform and their behaviour was 
observed. In the light-dark test the mice had access to either a light or a dark 
arena which were connected by an open door. The mice were placed in the 
light arena followed by observation of their behaviour. 
Locomotor activity (II, IV) was determined by placing the animal in a 
polycarbonate box followed by detection of horizontal movements using 
Ethovision software. 
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Circadian rhythm of locomotor activity (II) was determined in home cages 
using  photobeam activity frames. For the first seven days the mice were kept 
on a light-dark 12:12 h schedule, and thereafter the next seven days they were 
kept in constant darkness. 
Forced swim test (II) was performed by placing the animal in a large beaker 
containing water. Tail suspension test (II) was performed by taping the mouse 
by its tail into a vertical metal bar. In both tests, the mouse behaviour was 
video-recorded and subsequently visually observed using Ethograph software. 
These tests have used to assess depression-like immobility phenotype, relieved 
by antidepressants (Porsolt et al. 1977; Steru et al. 1985). 
Withdrawal symptoms (III) after subchronic flurazepam treatment were 
precipitated with 20 mg/kg (s.c.) flumazenil followed by visual observations of 
the symptoms that included jumping, digging, stretching, “wet-dog”—like 
shakes, forepaw tremor, paw treading, head twitching, writhing, circling 
behaviour, and pelvic elevation. 
Conditioned place preference (IV) was studied by pairing a saline injection 
with either plastic or metal floor material in the first session of the day, and 
morphine injection with the other floor type in the second session of the day. 
After the conditioning sessions, the mice were provided a choice session in 
which both floor types were present. In the choise session, either saline or 
morphine was injected to study state-dependency. The spatial location and 
distance moved was determined by Ethovision software. 
Morphine discrimination (IV) was conducted in operant chambers with two 
levers. Mice were trained to lever-press for sweetened condensed milk after 
injection of saline or morphine on a fixed ratio schedule. Subsequently the 
mice were tested for morphine-appropriate responding after injection of 
various testing doses of morphine. 
4.3 NEUROCHEMICAL METHODS 
Autoradiographic analyses (I, IV) were performed using various radioactively 
labeled ligands that bind to target proteins. The radioligands used were, [3H]-S-
AMPA to study binding to AMPA receptors, [3H]SYM 2081 to study binding 
to kainate receptors, [3H]MK-801 to study binding to NMDA receptors and 
GTP"[35S] to study opioid receptor signalling. For these analyses, mouse brains 
were dissected, frozen on dry ice, stored at -80 °C and later coronal sections 
were cut using a cryostat followed by thaw-mounting on glass slides. In 
general, the sections were incubated with a radioactive ligand in the presence 
or absence of a non-labeled ligand to determine specific and non-specific 
binding. After the incubation, the sections were exposed on a photographic 
film with plastic radioactive standards. The films were scanned for images, and 
the binding densities were determined by M5 software. 
Brain monoamines (I) were determined from brain samples using HPLC 
with electrochemical detection. For the analysis, the brain samples were 
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dissected using a brain mould, frozen on dry ice, stored at -80 °C and 
homogenized using an ultrasonic processor. 
Plasma testosterone (I) was determined using a radioimmunoassay. For the 
analysis, trunk blood was collected into heparinized tubes, centrifuged and 
plasma subjected for diethylether extraction prior to radioimmunoassay. 
The expression of c-Fos (II) in various brain regions was determined by 
immunohistochemical method. For the analysis, the brains were dissected, 
frozen on dry ice, stored at -80 °C, cut into coronal sections using cryostat and 
thaw-mounted on glass slides. After preliminary preprocessing of the samples, 
the sections were incubated with primary goat anti-c-Fos antibody and 
secondary biotinylated horse anti-goat antibody. Photographed sections were 
counted for c-Fos-positive cells using Image Proplus 6 software. Primary 
rabbit anti-tyrosine hydroxylase antibody and secondary biotinylated donkey 
anti-rabbit antibody were added when performing double-immunostaining for 
c-Fos and tyrosine hydroxylase (II). 
Flurazepam and desalkylflurazepam (III) were determined from blood 
plasma and brain tissue by liquid chromatography with mass spectrometric 
detection. For the analysis of blood plasma, trunk blood was collected into 
tubes containing ethylenediaminetetraacetic acid, centrifuged and plasma 
subjected for diethylether extraction. Brain tissue was homogenized using a 
mechanical processor. 
4.4 ELECTROPHYSIOLOGICAL METHODS 
AMPA/NMDA current ratio was determined ex vivo in the VTA DA neurons 
after systemic morphine injection. For the analysis, brains were dissected and 
midbrain slices were cut and studied with whole-cell patch-clamp recordings. 
The DAergic neurons were indentified by detection of hyperpolarisation-
activated cation current. Baseline EPSC was evoked by electrical stimulation. 
AMPA receptor-mediated currents were pharmacologically isolated by 
blocking NMDA receptors with (2R)-amino-5-phosphonopentanoate. 
4.5 STATISTICAL TESTS 
The results were tested using analysis of variance (ANOVA), followed by post-
hoc tests such as paired-samples t-test, independent-samples t-test, Bonferroni 
test, Newman-Keuls multiple comparison test, Fisher’s test, Duncan test, least 
signifcant difference post-test, or Wilcoxon matched-pair test, depending the 
number of groups in question and whether the data were parametric or non-
parametric. Correlations analysis was performed using Pearson’s correlation. 
Statistical analyses were performed using SPSS and GraphPad Prism softwares. 
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5 RESULTS AND DISCUSSION 
5.1 GLUA1 SUBUNIT-DEFICIENT MICE DISPLAY 
NORMAL PRIMARY BEHAVIOUR 
GluA1-KO mice were inspected for abnormalities in the primary behaviour 
including sensory reflexes and functions, motor performance, muscle function 
and transfer arousal followed by instant locomotor activity (I; III, Fig. 1). No 
differences were found in any of the tests of SHIRPA phenotype screen, 
suggesting that GluA1-KO mice are viable without overt sensory, muscular, 
motor or neurological disturbances. These data are substantiated by similar 
findings found elsewhere (Bannerman et al. 2004; Wiedholz et al. 2008; 
Fitzgerald et al. 2010). In summary, the normal primary behaviour enables the 
use of the mouse line for further experiments. This is important as numerous 
behavioural tests are based on the locomotion of the mouse or detecting place 
of a mouse based on locomotor activity. 
The phenotypic characterisation of the GluA1-KO mouse line was 
extended by observing the circadian rhythm of locomotor activity. The mice 
displayed a normal pattern of activity during light-dark 12:12 h (LD) schedule 
(II, Fig. 1C-D), as reported previously for mice (Schwartz & Zimmerman 
1990). When exposed to constant darkness in the dark-dark 12:12 h (DD) 
schedule, the mice continued to show circadian rhythm obtained during the 
previous LD cycle which then underwent a gradual phase advance (II, Fig. 1E-
F), which has also been reported for mice (Schwartz & Zimmerman 1990). 
These results are perhaps surprising considering the expression of glutamate 
AMPA receptor subunits in the suprachiasmatic nucleus, a main generator of 
the circadian rhythmicity in the mammalian brain (Ebling 1996). 
Anxiety profile of the GluA1-KO mouse line was found to be somewhat 
less anxious than WT mice (I, Fig. 3). The anxiety-related phenotypes have 
been extensively studied in GluA1-KO mouse line. It seems that this 
phenotype is a rather complex one since unchanged, increased and decreased 
anxiety have all been proposed (Bannerman et al. 2004; Mead et al. 2006; 
Fitzgerald et al. 2010). 
Neurochemical characterisation was performed to detect possible 
modifications in the glutamatergic system. [3H]-S-AMPA binding was shown 
to be decreased in the hippocampi of GluA1-KO mice (I, Fig. 5), providing 
more evidence to decreased AMPA receptor expression (Zamanillo et al. 1999; 
Mead and Stephens 2003). In keeping with the protein blotting results 
(Zamanillo et al. 1999), no changes in hippocampal [3H]MK-801 and [3H]SYM 
2081 binding were detected (I, Fig. 5), suggesting unaltered NMDA and 
kainate receptor expression, respectively.  
In GluA1-KO mouse line, the gria1 gene is non-functional for the entire age 
of the mouse, i.e. from the development to the adult age. In rats, AMPA 
receptor mRNA can be detected during the embryonic stage (Monyer et al. 
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1991). More specifically, the GluA1 subunit protein is expressed in rat brain at 
embryonic day E15.5, and the expression levels increase later at the postnatal 
stage (Martin et al. 1998). Synaptogenesis occurs in rodents at the first postnatal 
weeks, and functional AMPA receptors are present, forming synapses from the 
very beginning (for review, see Groc et al. 2006). Thus, the absence of GluA1 
subunit in the GluA1-KO mouse line may lead to possible compensatory 
modifications of other genes, these genes’ expression and post-transcriptional 
regulation of the resulting protein products. This issue has been addressed in a 
study performing a whole genome screen of the hippocampal tissue from the 
GluA1-KO mouse line (Zhou et al. 2009). The screening yielded 38 genes that 
were regulated more than 30%. Of these genes, the changed expression was 
confirmed in protein level for the obligatory NMDA receptor subunit GluN1 
and calcium!calmodulin-dependent protein kinase II alpha (CaMK2A). 
Upregulation of GluN1 may suggest a need to compensate for the slightly 
reduced AMPA receptor-mediated transmission (Table 3 and section 2.8.1), 
and downregulation of CaMK2A may mirror a need to compensate for the 
increased calcium influx. Thus, some compensation occurs when one calcium 
regulator is absent. From this data it can also be seen that no other AMPA 
receptor subunits were found to be altered despite the lack of GluA1. Finally, 
although the GluA1-KO mouse line is viable without any gross abnormalities, 
one cannot exclude the fact that the gria1 gene deletion-induced 
compensations that take place either during development or during adult age 
may affect the present results. Nevertheless, the role of this subunit in various 
forms of plasticity in the CNS has been specified and clarified by use of this 
mouse line. 
5.2 POSITIVE PLASTICITY IN GLUA1-KO MOUSE 
LINE 
5.2.1 GLUA1 SUBUNIT IS ESSENTIAL FOR PLASTICITY 
ENABLING NORMAL RESPONDING TO 
CHANGED SOCIAL STATE IN ENVIRONMENT 
 
Agonistic behaviours were studied in GluA1-KO mouse line in various 
paradigms to acquire a wide-ranging picture of the involvement of GluA1 
subunit in plasticity that is required for normal behaviour in mouse social 
interaction (Miczek et al. 2001). When GluA1-KO mice were isolated for 
various periods of time and then subjected to resident-intruder encounter as 
resident mice, they showed less agonistic behavioural elements towards the 
intruder than the WT littermate control mice (I, Fig. 1A and Table 1). Even 
long-lasting isolation of 30 days or agonistic encounter without isolation did 
not evoke normal aggressive behaviour in GluA1-KO mice (I, Fig. 1B and 
Table 2). Finally, the results from interline encounters on a new territory 
substantiated the previous findings and further specified the changed 
 56 
behavioural strategy of GluA1-KO mouse line as more defensive-like in 
situations when attacked by another mouse (I, Fig. 2 and Table 2). 
GluA1-KO mice showed aggressive behaviour in some social encounters 
suggesting reduced, but not completely absent aggressive behaviour in these 
mice. However, when the social encounter in resident-intruder test was 
repeated thus providing the mice new opportunities to change their behaviour 
(I, Fig. 1A and Table 2), GluA1-KO mice still showed remarkably reduced 
aggression which is a clear indication of the lacking ability to adapt to a new 
situation (Miczek et al. 2001). Thus, although the GluA1-KO mice were 
constantly at a disadvantage in the social interaction compared to WT mice, 
they showed no indication to enhance their status in the social situation. This 
might have fundamental deleterious influence on survival in the changing 
habitat of the mice. These results suggest that the plastic processes mediated 
by GluA1 subunit are required for successful encounter in changed social 
circumstances. 
These data are supported by a range of pharmacological findings on mouse 
aggression. Non-competitive AMPA receptor antagonist GYKI 52466 was 
found to reduce aggression in a mouse line selectively bred for high aggression, 
while competitive antagonists CNQX and NBQX were less effective on 
aggressive behaviours (Vekovischeva et al. 2007). Although these antagonists 
are non-selective over various AMPA receptor subtypes, they nevertheless 
provide another piece of evidence that decreased activation of AMPA 
receptors is linked to reduction in aggression. 
The lack of aggressive behaviour was found to be sex-dependent, as female 
mice of GluA1(R/R) line showed similar agonistic behaviour as WTs (I, Table 
2). Thus, the deletion of GluA1 subunit renders only males deficient in 
aggressive behaviour. However, this was not caused by abnormal levels of 
plasma testosterone or brain monoamines (I, Fig. 4), despite both have been 
clearly linked to aggressive behaviour (Siever 2008). The normal testosterone 
levels in male GluA1-KO mice may be a surprising finding, since accumulating 
lines of evidence point to the role of AMPA receptors in regulation of 
testosterone levels. First, glutamatergic activation of gonadotropin-releasing 
hormone neurons is mainly mediated by AMPA receptors (Spergel et al. 1999). 
Second,  AMPA receptors co-localise with androgen or estrogen receptors in 
hypothalamic neurons (Diano et al. 1997). Finally, to close the circle, gonadal 
steroids testosterone and estradiol regulate AMPA receptor expression in the 
hypothalamus (Diano et al. 1997). Moreover, deletion of the GluA2 subunit in 
gonadotropin-releasing hormone neurons failed to alter testosterone levels 
(Shimshek et al. 2006). Despite this, GluA2-KO mice show a profound lack of 
aggression (Shimshek et al. 2006), thus substantiating the findings that highlight 
the importance of AMPA receptors as mediators of agonistic behaviours. 
There is another possible, although also a plasticity-dependent explanation 
for the reduced aggression observed in GluA1-KO mice. Agonistic behaviours 
largely develop in a social context over time, and usually significant experience 
with other mice is required before mice show agonistic behaviour as adults 
(King and Gurney 1954; King 1957; Miczek et al. 2001). Thus, it could be 
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assumed that there is a significant component of learning in the development 
of the aggressive behaviour in mice. In GluA1-KO mice, which show deficient 
learning in various tasks (Table 2), may also have a reduced capability to learn 
aggressive behaviours from their counterparts, or from their parents. Hence, 
the reduced aggression in GluA1-KO mice may be attributable to impaired 
imprinting behaviour (Spalding 1872), a phenomenon that enables learning 
critical behaviours from the parents and previously suggested to underlie 
aggressive behaviour in mice (Mugford and Nowell 1972). It should be noted 
that imprinting might be a consequence of deficient behaviour either in the 
parents or in the offspring. However, the former is not supported for two 
reasons. First, although the GluA1-KO and WT mice were bred using 
heterozygous mice, the WT mice showed robust agonistic behaviour in all 
behavioural situations of social interaction (I). Second, haploinsufficiency of 
GluA1 subunit spares social behaviour in mice (Wiedholz et al. 2008) 
implicating that heterozygous parents set a normal example of social behaviour 
to their offspring. Finally, imprinting has previously been suggested to depend 
on glutamate receptor-mediated plasticity (McCabe and Horn 1988). 
5.2.2 SPATIAL NOVELTY INDUCES HYPERACTIVITY 
AND EXCESSIVE NEURONAL ACTIVATION IN 
GLUA1-KO MICE 
 
Processing of novel signals was studied in GluA1-KO mice by exposing them 
to spatial novelty and then measuring their locomotor activity. GluA1-KO 
mice displayed increased locomotor activity in the novel cage from the 
beginning of the observation session, suggesting that these mice are hyper-
responsive to this type of change in their environment (II, Fig. 1A-B). The 
strong novelty-induced response was sustained for 4 hours as compared to WT 
control mice, although gradually decreasing to the baseline level (II, Fig. 1A-
B). This suggests that the intrasession habituation is somewhat impaired in 
these mice. The finding of novelty-induced hyperactivity is a very robust one, 
and has been documented in various paradigms (Table 2). In earlier studies 
also deficient intersession habituation has been detected (Vekovischeva et al. 
2001; Wiedholz et al. 2008). These data suggest a critical role for GluA1 
subunit-mediated neuroplasticity in normal processing of novel signals in a task 
of nonassociative learning (Leussis and Bolivar 2006). 
The pharmacological data on AMPA receptor antagonists substantiates 
these findings by demonstrating that AMPA receptor antagonist CNQX 
reduces habituation when microinjected to the hippocampus (Izquierdo et al. 
1993; Vianna et al. 2000). Furthermore, targeting NAc with another AMPA 
receptor antagonist DNQX reduces habituation, but interestingly DNQX also 
is able to decrease reaction to spatial novelty when injected just prior to 
exposure to novelty (Roullet et al. 2001). The reciprocal roles of GluA1 and 
GluA2 subunits in responding to novelty are supported by findings of GluA2-
KO mouse line (Jia et al. 1996). Contrary to the behaviour of GluA1-KO mice, 
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GluA2-KO mice show hypolocomotion in response to spatial novelty, 
although this feature has not been studied in more detail (Gerlai et al. 1998). 
Exposure to novelty induced brain region-dependent increase in c-Fos 
protein expression (II, Table 1), creating a similar pattern of activation as 
described earlier (Kovacs 1998). c-Fos as a marker for the activated cells 
needed to fullfil the following criteria: (i) quick initiation of expression due to 
the rapid onset of hyperlocomotion of GluA1-KO mice in response to spatial 
novelty, (ii) maximal expression of the marker should have mirrored the time 
spent in novelty which was 2 h, and (iii) negligible expression in normal state 
of an animal. As the induction of c-fos mRNA occurs within couple of minutes, 
the maximal expression of c-Fos occurs between 1-3 h and expression is 
minimal in normal state, c-Fos can be summarised to reflect the acute spatial 
challenge in GluA1-KO mice (Kovacs 1998). The basal c-Fos expression 
remained unchanged in GluA1-KO mice with the exception of midbrain 
region substantia nigra in which GluA1-KO mice had more c-Fos positive cells 
although this region did not respond to novelty (II, Table 1). However, after 
novelty GluA1-KO mice had more c-Fos positive cells in certain regions 
compared with WT mice (II, Table 1). Especially the hippocampal subregions 
were more activated in GluA1-KO mice (II, Fig. 2). The main cortical input 
region to the hippocampus, the entorhinal cortex, was also activated more in 
GluA1-KO mice than in WT controls (II, Fig. 3). These data show that in 
GluA1-KO mice the higher responding to novelty is linked with pronounced 
neuronal activation of hippocampus and its main cortical input region, which 
might underlie the deficient detection of novelty (Vinogradova 2001). 
Generation of new neurons (neurogenesis) in the adult hippocampal 
dentate gyrus was found to be reduced in GluA1-KO mice (II, Fig. 4), but the 
survival of the newly-born neurons increased (II, Fig. 4). The fate of the 
proliferated cells either to neurons or glia was not different between GluA1-
KO and WT mice (II). These data are of interest because neurogenesis has 
been implicated in the etiology of depression (Jacobs et al. 2000), a psychiatric 
disorder the GluA1-KO mouse line has been suggested to model (Chourbaji et 
al. 2008). Also two other animal models show alterations in neurogenesis. In 
chronic mild stress model, both reduced hippocampal neurogenesis and GluA1 
subunit levels were observed with normal levels of novelty exploration (Toth et 
al. 2008). In olfactory bulbectomy, reduced hippocampal neurogenesis was 
linked to novelty hyperactivity (Jaako-Movits and Zharkovsky 2005). However, 
in forced swim and tail suspension tests which both have predictive validity in 
depression studies (Steru et al. 1985), GluA1-KO mice show no depression-like 
phenotype (II, Fig. 6C). On the contrary, GluA1-KO mice display decreased 
immobility, rather suggesting acute mania-like behaviour. Indeed, spatial 
novelty-induced hyperactivity that undergoes clear habituation (spiking 
hyperactivity) has been documented in patients with bipolar mania (Perry et al. 
2009). Also, in support of this, both acute and chronic treatment with the 
selective serotonin reuptake inhibitor escitalopram failed to alter novelty 
hyperactivity in GluA1-KO mice (II, Fig. 6A-B, D). Finally, novelty 
hyperactivity shows correlation with reduced proliferation of newly born cells 
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(Lemaire et al. 1999) suggesting that neurogenesis is functionally linked to 
processing novel information. However, in another study using mice with 
genetical reduction in proliferation, no alterations in novelty-induced 
locomotor activity were observed (Dupret et al. 2008). 
Interestingly, AMPA receptor positive modulator CX546 failed to alter 
hyperlocomotion in GluA1-KO mice (II, Fig. 1B). However, the AMPA 
receptor antagonist NBQX resulted to partial rescue of normal response to 
novelty (II, Fig. 1A) further supporting the notion of glutamatergic 
overactivation in the brains of GluA1-KO mice. 
Hippocampal LTP and LTD have previously been linked to novelty 
exposure (Manahan-Vaughan and Braunewell 1999; Li et al. 2003). These 
cellular plastic events represent putative correlates of learning and memory, 
and thus may show importance in the processing of novel signals in e.g. by 
encoding of spatial information. Although the classical hippocampal LTP is 
absent in GluA1-KO mice (Zamanillo et al. 1999), GluA1 subunit-independent 
LTP is largely spared (Hoffman et al. 2002; Romberg et al. 2009). Thus, this 
form of cellular plasticity may be recruited in GluA1-KO mice, and may 
underlie the eventual behavioural habituation to novelty in these mice (II, Fig. 
1A-B). However, the facilitation LTP or LTD by exposure to novelty has not 
been studied in GluA1-KO mice (Table 3). 
Furthermore, it is intriguing to note that the increased neuronal activation 
in the hippocampi of GluA1-KO mice may lead to increased cellular plasticity. 
In the behavioural level, this view is supported by data indicating that while 
short-term spatial memory is deficient in GluA1-KO mice, they show 
increased long-term spatial memory (Sanderson et al. 2009). Thus, an 
alternative explanation emerges, suggesting that in some instances GluA1-KO 
mice may have superior plasticity than WT mice. In line with this, c-fos has been 
reported to play a role in plasticity (Fleischmann et al. 2003). 
5.3 NEGATIVE PLASTICITY IN GLUA1-KO MOUSE 
LINE 
5.3.1 GLUA1-KO MOUSE LINE RETAIN SENSITIVITY 
TO ACUTE BENZODIAZEPINE FLURAZEPAM, 
BUT SHOW IMPAIRED DEVELOPMENT OF 
TOLERANCE AND INCREASED WITHDRAWAL 
 
The pharmacology of flurazepam was studied in GluA1-KO mice using 
modified SHIRPA behavioural test battery as described (III, Table 1). First, 
acute sensitivity was determined by injecting flurazepam in acute 40 mg/kg 
(s.c.) dose and 30 min later observing mouse behaviour. Flurazepam elicited a 
clear sedative and muscle relaxant pattern of effects in motor performance, 
muscle relaxation, sensorimotor parameters and body temperature (III, Fig. 1) 
in both GluA1-KO and WT mice, with the exception that startle response was 
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somewhat decreased only in GluA1-KO mice. Concentrations of flurazepam 
and its main metabolite, desalkylflurazepam, were identical in GluA1-KO and 
WT mice 2 hours after the injection of 60 mg/kg (s.c.) (III, Table 2). These 
data suggest that the GABAergic system as the main inhibitory 
neurotransmitter system is largely normal despite the lack of GluA1 subunit, 
which is one of the main contributors to the counterbalancing excitatory 
glutamatergic system. Thus, this might suggest that no GluA1 deletion-induced 
compensations in the genes or their expression were extended to the 
GABAergic system. 
Intact flurazepam sensitivity in GluA1-KO mouse line allowed 
determination as to whether the neuroplastic processes mediating chronic 
effects of flurazepam are dependent on GluA1 subunit. The subsequent 
behavioural investigations were twofold. First, recovery after an acute dose of 
flurazepam was determined. Second, development of tolerance to the effects 
of flurazepam was studied followed by observation of withdrawal. 
After an acute 40 mg/kg (s.c.) dose of flurazepam, GluA1-KO mice needed 
more time to recover, as evidenced by gait and pelvic elevation tests (III, Fig. 
2; Fig. 3A). There was a genotype-independent difference between the sexes; 
females recovering quicker than males. These effects were not due to 
pharmacokinetics of flurazepam, as blood and brain content of flurazepam 
were identical between GluA1-KO and WT mice after the recovery (III, Fig. 
3B-C). Desalkylflurazepam was detected at higher blood and brain 
concentrations in WT male mice than in others (III, Fig. 3D-E). These data 
suggest that glutamate-driven plasticity is recruited already when mice are 
under the influence of flurazepam or its metabolites. More specifically, these 
data suggest that the lack of GluA1-dependent plasticity renders mice 
incapable of developing normal acute tolerance to the sedative and muscle 
relaxant effects of flurazepam already at the very first stage. 
Subchronic treatment with high doses of flurazepam resulted in partial 
development of tolerance in both mouse lines (III, Fig. 4). However, GluA1-
KO mice developed less tolerance than WT mice. The pharmacokinetic 
parameters after the subchronic treatment were identical between GluA1-KO 
and WT mice (III, Table 2). Forty-eight hours after the cessation of 
subchronic treatment, the flumazenil-precipitated withdrawal symptoms were 
scored. GluA1-KO mice had more severe withdrawal than WT mice (III, Fig. 
5). 
Changes in pharmacokinetics of flurazepam and desalkylflurazepam partly 
explain the development of tolerance in mice, although there were no 
differences between the pharmacokinetic parameters between GluA1-KO and 
WT mice. More specifically, the desalkylflurazepam to flurazepam 
concentration ratios were highly increased in both genotypes after the 
subchronic flurazepam treatment, documenting an induction of flurazepam 
metabolism. 
 
These results demonstrate that GluA1 subunit-mediated neuroplasticity 
plays a role in both acute and repeated benzodiazepine administration. After an 
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acute dose, AMPA receptors have been implicated in benzodiazepine-induced 
plasticity localised to VTA DA neurons by showing increased AMPA/NMDA 
receptor current ratio and inward rectification (Heikkinen et al. 2009; Tan et al. 
2010). This plasticity is thought to be mediated by GluA2-lacking AMPA 
receptors, which undergo rapid trafficking to the cell membrane and are 
permeable to calcium (Shi et al. 2000). The GluR2-lacking receptors are most 
likely GluA1 homomeric receptors, since GluA3 homomers show no 
rectification (Shi et al. 2001). Also, the hippocampus shows similar molecular 
and cellular plasticity (Hayashi et al. 2000), although acute benzodiazepine-
induced plasticity has not been studied in this region despite it displays the 
most abundant AMPA receptor expression in the CNS. 
Likewise, chronic treatment with flurazepam leading to dependence has 
been shown to cause an increase in GluA1 subunit-containing AMPA 
receptors in the hippocampus (Song et al. 2007), and pharmacological 
intervention using AMPA receptor antagonists reduces benzodiazepine 
treatment-induced withdrawal (Steppuhn and Turski 1993). However, the data 
showing reduced capability to develop tolerance but increased withdrawal in 
GluA1-KO mice are not well suited to these previous findings. In GluA1-KO 
mice, reduced tolerance due to deficient glutamate-mediated plasticity might 
have eventually resulted in greater inhibitory state, thus finally resulting in 
increased withdrawal when the positive modulation of GABAA receptors was 
removed by the benzodiazepine antagonist flumazenil. 
5.3.2 MORPHINE-INDUCED STATE-DEPENDENCY IS 
ABSENT IN GLUA1-KO MOUSE LINE 
 
GluA1-KO mice were studied in an associative learning paradigm of 
conditioned place preference to clarify the role of GluA1 subunit in morphine-
induced neuroplasticity. GluA1-KO mice developed sensitisation to 
intermittently administered morphine (IV, Fig. 1-2). Although GluA1-KO 
mice did not show acute morphine-induced increase in locomotor activity, they 
regained this effect in subsequent trials (IV, Fig. 1-2). Place conditioning was 
evident in GluA1-KO mice as they approached morphine-paired conditioning 
stimulus in the test trial (IV, Fig. 3). Deficient (Dong et al. 2004) or intact 
(Mead and Stephens 2005) place preference to cocaine has previously been 
reported in GluA1-KO mice. The former study utilised a biased apparatus 
while both the latter and the current studies used an unbiased setting thus the 
difference in place conditioning results may be due to methodological 
differences (Cunningham et al. 2003). Morphine-induced state-dependency was 
probed in both saline and morphine states. While WT mice showed the 
greatest expression of place preference when tested in morphine state, GluA1-
KO mice displayed no place preference (IV, Fig. 3). Both mouse lines showed 
a moderate place preference when tested in a saline state, that is, test was 
performed in a different state than the mice were conditioned to (IV, Fig. 3). 
An intact detection of morphine signal was demonstrated by normal morphine 
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discrimination (IV, Fig. 4), and also brain regional "-opioid receptor signalling 
was unmodified in GluA1-KO mice (IV, Fig. 6). Taken together, glutamate 
neuroplasticity was suggested to play a role in state-dependency without 
modifications in the molecular target of morphine, the "-opioid receptor.  
Few molecular or cellular correlates of state-dependency have previously 
been described. Cortical muscarinic acetylcholine receptors may mediate state-
dependency (Shulz et al. 2000), and morphine-induced state-dependency has 
been shown a receptor subtype-selectivity (Bruins Slot and Colpaert 1999). In 
the etiology of addiction, VTA DA cells have been shown an established role 
(Hyman and Malenka 2001). Therefore, it is interesting to note that the same 
area has been implicated in state-dependency (Zarrindast et al. 2005). The 
electrophysiological data presented a more detailed analysis of VTA DA cells 
as a putative cellular correlate of state-dependency by showing absence of 
capability for morphine-induced neuroplasticity in GluA1-KO mice (IV, Fig. 
5), displaying deficient state-dependency. 
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6 SUMMARY 
The understanding of the roles the main excitatory system in the CNS (in 
particular driven by neurotransmitter glutamate) plays in brain function has 
undergone a significant increase during the last decades. The glutamatergic 
system, that was initially thought to act as a mere molecular accelerator of 
neurons, is now believed to function as an important mediator of plastic 
changes of the CNS. At first, the functional significance of glutamate 
neuroplasticity was linked to the mechanisms of learning and memory (White et 
al. 1977). However, the list of issues that relate glutamate to plasticity is 
growing, but also plasticity per se has gained more interest as a general 
mechanism behind various physiological and pathological states.  
The current studies expand these findings by describing the importance of 
glutamate AMPA receptor GluA1 subunit in two main types of plasticity. 
Positive plasticity, that is beneficial to the individual by enabling 
accomplishment of various tasks and eventually is important for survival, is 
dependent on GluA1 subunits. GluA1 subunit has been implicated in positive 
plasticity by demonstrating deficient working memory in GluA1-KO mice 
(Reisel et al. 2002) while reference memory is functional in these mice 
(Zamanillo et al. 1999). Negative plasticity, having potentially harmful 
outcomes, was shown to be attributable to GluA1 subunit-mediated 
neuroplastic processes caused by two different classes of drugs of abuse.  
GluA1-KO mouse line has been linked to various psychiatric disorders 
(Chourbaji et al. 2008; Wiedholz et al. 2008; Fitzgerald et al. 2010). For example, 
GluA1 has been linked to the etiology of schizophrenia (Magri et al. 2006). 
More specifically, a reduction in GluA1 subunit mRNA expression has been 
reported in the post-mortem frontal cortex of schizophrenia patients (Sokolov 
1998). Interestingly, the reduction was reversed in patients treated with 
antipsychotic medication. Thus, it may be possible to target GluA1 subunit-
containing AMPA receptors with AMPA receptor positive allosteric 
modulators in schizophrenic patients, should subunit-selective ligands become 
available. In bipolar disorder, reduction in the expression of striatal GluA1 
mRNA has been reported in post-mortem brains of patients (Meador-
Woodruff et al. 2001).  
Interestingly, no change in GluA1 subunit mRNA or protein level was 
detected in post-mortem VTA or NAc from cocaine overdose victims (Tang et 
al. 2003; Hemby et al. 2005), although GluA1 has been demonstrated a role in 
the effects of cocaine in rodents (Dong et al. 2003). However, in the post-
mortem amygdala of cocaine and heroin abusers, a positive correlation was 
found between GluA1 subunit and postsynaptic density protein-95, while this 
correlation did not emerge in control subjects (Ökvist et al. 2011). This might 
suggest a dysregulated synaptic function in drug abusers, although the direct 
role of this positive correlation is unclear. 
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Specific aspects of learning and memory were shown to be GluA1-
dependent. Non-associative learning in spatially novel place is deficient in 
GluA1-KO mouse line, and has previously been shown a glutamate-dependent 
component (Izquierdo et al. 1993). Although pavlovian conditioning is intact in 
these mice, GluA1 subunit is a mediator of state-dependency in this type of 
associative learning. 
The mouse model that was used in the present studies is based on a global 
deletion of GluA1 subunit, that is, every brain region and every cell is devoid 
of GluA1 subunit-containing AMPA receptors from the development to the 
adult age. Since there are no subunit-selective pharmacological ligands available 
to target AMPA receptor subtypes, this genetical model offered an alternative 
way to study the present issues. However, it would be interesting to study the 
plasticity-related issues presented here with such ligands, since with a 
pharmacological approach it would be possible to avoid much, if not all, of the 
compensations that are caused by the global deletion of GluA1 subunit. 
Furthermore, these and other plasticity-related issues would need to be studied 
in more detail with other, e.g. conditional transgenic and optogenetic 
technologies, to elucidate the roles of specific neuronal populations. 
Taken together, targeting GluA1 subunit may be beneficial in counteracting 
drug-induced malignant negative plasticity e.g. by possibly reducing relapsing 
behaviour in drug addictions. However, the results of this study on positive 
plasticity suggest a cautious approach on this matter, as there may be harmful 
effects on some fundamental behaviours such as learning and memory, 
processing of novel signals and responding in social environment. 
Furthermore, there is an increasing body of literature suggesting that 
enhancement of AMPA signalling with AMPA receptor positive modulators 
(see section 2.7.6) may be useful in disorders such as Alzheimer’s disease, 
Parkinson’s disease and depression (O’Neill et al. 2004). Although the present 
results suggest possible beneficial effect of targeting GluA1-containing AMPA 
receptors in counteracting addiction disorders, the potentiation of AMPA 
signalling may lead to increased vulnerability in addiction-related states. Thus, 
these results may be of importance for future drug development in highlighting 
both possible new avenues for new indications, and also possible adverse 
effects that might emerge. In summary, these results suggest that glutamate 
AMPA receptor GluA1 subunit plays a wide role in neuroplasticity in the CNS, 
and they further strengthen the role of glutamatergic system as a mediator of 
plastic processes. 
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7 CONCLUSIONS 
1. The GluA1-deficient mouse line is viable and shows novelty-induced 
hyperactivity but no other overt changes in the basic behaviour or in 
the expression of other types of glutamate receptors. 
 
2. GluA1 subunit is pivotal for plasticity that enables successful 
performance in agonistic encounters.  
 
3. Normal response to spatial novelty requires GluA1 subunit. In the 
brain of GluA1-KO mouse, the increased novelty-induced activation is 
mainly localised to the hippocampus and its input area entorhinal 
cortex. 
 
4. The acute pharmacological effects of benzodiazepine flurazepam are 
unchanged in the absence of GluA1 subunit, but development of acute 
tolerance to flurazepam requires the GluA1 subunit. 
 
5. GluA1 subunit is necessary for functional morphine-induced state-
dependency. 
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